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Mitochondrial Metabolism as a Therapeutic
Target for Pancreatic Cancer
Abstract
Simon C. Shin, Ph.D.
University of Nebraska Medical Center, 2020
Advisor: Michael A. Hollingsworth, Ph.D.
ABSTRACT
Mitochondrial metabolism plays a central role in PDAC tumor progression and
represents a promising avenue for cancer therapy. Data presented in the first half of this
dissertation demonstrate the importance of mitochondria-dependent metabolic flexibility
under stressful environmental conditions. While a causal relationship between oncogenic
drivers and altered metabolism is well established, less is known regarding the modulation
of cancer metabolism by the microenvironment. We found that low extracellular pH, a
common feature of solid tumors, provoked PDAC cells to decrease glycolysis and become
resistant to glucose starvation. This was accompanied by increased dependency on
mitochondrial metabolism, in which long-chain fatty acids became a primary fuel source.
Consistent with previous reports, low pH enhanced tumor cell invasive capacity. A novel
finding was that limiting PDAC metabolic flexibility by either depletion of oxidative
phosphorylation capacity or the pharmacological inhibition of fatty-acid oxidation
prevented invasion induced by low extracellular pH. These results suggest that targeting
fatty-acid oxidation may be a viable adjunct strategy for preventing metastatic progression
of pancreatic cancer mediated by the acidic tumor compartment.
The studies in the latter half of this dissertation investigate cardiolipin biosynthesis
as a novel approach for targeting mitochondrial function in cancer cells. Cardiolipin is a
mitochondrial-specific phospholipid found at increased levels following the activation of
oncogenes. Turnover of cardiolipin is remarkably slow in differentiated cells, providing a
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potential therapeutic window for cancer therapy. We found that PTPMT1, a mitochondrial
phosphatase involved in the biosynthesis of cardiolipin, sustained growth of pancreatic
cancer cells both in vitro and in vivo. Loss of PTPMT1 resulted in a time-dependent
decrease in proliferation that correlated with decreased cardiolipin levels. Depletion of
cardiolipin caused significant alterations to the mitochondrial ultrastructure and impaired
OXPHOS and TCA anaplerosis. While this did not directly lead to increased cell death,
PTPMT1-deficient cells displayed increased dependence on glycolysis and were highly
vulnerable to glycolytic inhibition. Together, the results from this dissertation highlight the
importance of mitochondrial metabolism for supporting malignant progression and identify
cardiolipin biosynthesis as a novel therapeutic target.
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Chapter I: Introduction
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Pancreatic Cancer
Epidemiology
Pancreatic cancer is the 11th most common cancer in the United States with
approximately 56,770 newly diagnosed cases in 2019 [1]. With 45,750 estimated deaths
attributed to pancreatic cancer, it is also the third leading cause of cancer-related deaths
[1]. These statistics reflect the exceptional lethality of pancreatic cancer. Furthermore,
while the overall mortality rates of all cancers have dropped 27 percent in the past 25
years, pancreatic cancer is among the few exceptions for which death rates have
continued to rise [1]. Based on current projections, pancreatic cancer is expected to
become the second leading cause of cancer-related death in the United States by 2030
[2].
While the etiology of pancreatic cancer is unknown, certain risk factors have been
identified. About 10 percent of patients have a family history of pancreatic cancer [3].
Germline mutations (BRCA2 and CDKN2A) and inherited syndromes, such as Lynch
syndrome and Peutz-Jeghers syndrome, substantially increase an individual’s risk of
developing the disease [3]. Aside from family history, cigarette smoking is the most wellestablished risk factor. Cigarette smoking is predicted to nearly double the risk for
pancreatic cancer, a risk that persists at least a decade following cessation [4]. New-onset
diabetes and obesity are also positively associated with increased incidence of pancreatic
cancer [5].

Molecular and Histopathology
Pancreatic ductal adenocarcinoma (PDAC) is the most common neoplasm (about
90 percent) that can arise from the pancreas. Hence, the terms “PDAC” and “pancreatic
cancer” are often used synonymously. It is an invasive mucin-producing tumor with duct-
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like structures and dense stromal fibrosis [5]. Three main types of non-invasive precursor
lesions can give rise to PDAC: (i) pancreatic intraepithelial neoplasia (PanIN), (ii)
intraductal papillary neoplasm (IPMN), and (iii) mucinous cystic neoplasm (MCN) [6]. Most
ductal adenocarcinomas are considered to arise from PanIN lesions, which are formed by
metaplasia and proliferation of the ductal epithelium [7]. These lesions are graded (low
grade or high grade) based on the degree of dysplasia and the presence of atypical
architecture. While PanIN lesions are very common in older individuals, only a small
fraction progress to invasive cancer [7]. IPMNs and MCNs are less common cystic
precursor lesions of PDAC. IPMNs are mucinous cysts arising from the pancreatic duct
system while MCNs occur almost exclusively in women and are accompanied by an
underlying ovarian-type stroma [5].
Four major genetic alterations are commonly found in PDAC [8]. About 90 percent
of tumors contain activating mutations in the KRAS oncogene, which encodes a small
GTPase that mediates downstream signaling important for proliferation, survival, and
differentiation [9]. Inactivating mutations in the tumor suppressor TP53 gene are present
in over 50 percent of pancreatic cancers [9]. In genetically engineered mouse models,
KRAS and TP53 mutations are sufficient to induce spontaneous pancreatic tumors [10].
Somatic mutations are also frequently found in the cell-cycle regulator CDKN2A and the
tumor suppressor SMAD4, which mediates signaling downstream of the TGF receptor
[8].

Prognosis and Management
With a 5-year survival of only 8 percent, pancreatic cancer has the highest mortality
rate among all major cancers [1]. Surgical resection remains the only chance for a potential
cure, but fewer than 20 percent of patients are diagnosed early enough to be candidates
[11]. Late diagnosis is mostly due to the fact that many symptoms of pancreatic cancer
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are non-specific and appear late when the tumor has already advanced. Nevertheless,
approximately 80 percent of patients that undergo surgical intervention will die of
recurrence within 5 years [12], suggesting that metastasis went undetected at the time of
diagnosis. This may partially be due to the propensity of pancreatic cancer to disseminate
early in development [13].
For advanced PDAC, the single agent gemcitabine has been the standard of care
for more than two decades [14]. In 2011, the FOLFIRINOX chemotherapy regimen was
approved, which increased overall survival by 4.3 months, but was not well tolerated by
most patients due to extreme toxicity [15]. More recently, the gemcitabine/nab-paclitaxel
combination was shown to increase life-expectancy by 2 months compared to gemcitabine
alone [16]. While targeting oncogene-driven signaling pathways represents a clinically
validated approach for several devastating diseases, KRAS mutations, which are reported
in up to 90 percent of PDAC patients, currently remain undruggable [17]. The only targeted
therapy approved for PDAC is the EGFR inhibitor erlotinib, which extends life by less than
a month when used in combination with gemcitabine [18]. Even the recent breakthroughs
of cancer immunotherapy, such as PD-1 and CTLA-4 checkpoint blockade, have not
translated to success in the clinical setting for PDAC [19]. Overall, advancements in
therapy for PDAC have been underwhelming, with no treatment regimen extending life
longer than 1 year from diagnosis.
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Mitochondria in Cancer Metabolism
Cancer cells have unique metabolic requirements to sustain malignant
progression. Due to irregular vasculature and the cadre of immune and stromal cells, the
tumor microenvironment often imposes several challenges that cancer cells need to
overcome, including poor oxygen and nutrient supply. In order to grow and survive under
these conditions, cancer cells rely heavily on mitochondria to utilize various sources of
carbon as needed for bioenergetic and biosynthetic purposes. This dependence on
mitochondria for metabolic flexibility represents a vulnerability that could be exploited
therapeutically. The following review will highlight important functions of mitochondria as
they relate to tumorigenesis and briefly discuss the current and potential therapeutic
strategies for targeting mitochondrial metabolism.

Warburg Hypothesis: Mitochondrial Impairment and Cancer
Nearly a century ago, Otto Warburg and his colleagues made the seminal
observation that cancer cells exhibit elevated glycolysis and lactate production even in the
presence of adequate oxygen tension [20]. This phenomenon, known as aerobic
glycolysis or “Warburg effect,” led to the hypothesis that defects in mitochondrial
respiration were the underlying causes of cancer [21]. While aerobic glycolysis is a
common feature of most tumors and provides the basis for
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F-deoxyglucose positron

emission tomography (FDG-PET) imaging of neoplasms, overwhelming evidence now
suggest that oncogenes rather than mitochondrial defects are the primary driving force
behind metabolic alterations and malignant transformation. Nonetheless, mitochondrial
defects can contribute to tumorigenesis by at least two important mechanisms: generation
of mitochondrial reactive oxygen species (ROS) [22] and accumulation of oncometabolites
[23].
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Somatic mutations in mitochondrial DNA (mtDNA) that interfere with efficient
oxidative phosphorylation (OXPHOS) can increase oxyradicals that contribute to genomic
instability and trigger oncogenic signal transduction. In a prostate cancer model, cybrid
transfer of mtDNA ATP6 T8993G mutation caused a significant increase in ROS
generation and a sevenfold increase in tumor size [22]. Likewise, G13997A and
13885insC mutations in the gene encoding NADH dehydrogenase subunit 6 (ND6) were
found to confer high metastatic potential, which could be attenuated with ROS scavengers
[24]. Aside from mtDNA mutations, accumulation of dysfunctional mitochondria over time
can also lead to increased ROS. Mitophagy is a special type of autophagy in which
impaired mitochondria are selectively degraded. One of the key regulators of mitophagy,
parkin, has been documented to be deleted in some breast and ovarian tumors [25].
Furthermore, parkin-null mice were found to be more susceptible to spontaneous liver
tumors [26].
Abnormal accumulation of metabolites due to defects in nuclear-encoded
mitochondrial enzymes can also contribute to malignant transformation. Loss-of-function
mutations in the succinate dehydrogenase (SDH) complex subunits, which cause
succinate

buildup,

have

been

linked

to

hereditary

paragangliomas

and

pheochromocytomas [27]. Fumarate accumulation caused by mutations of fumarate
hydratase (FH) can drive renal cell carcinoma, familial leiomyoma, and uterine fibroids
[28]. Gain-of-function mutations in isocitrate dehydrogenase 1, cytosolic (IDH1) and
isocitrate dehydrogenase 1, mitochondrial (IDH2) can lead to the synthesis of 2hydroxyglutarate (2-HG) from -ketoglutarate (-KG). IDH1 and IDH2 mutations have
been found in low-grade gliomas and acute myelogenous leukemias [29]. Fumarate,
succinate and 2-HG are oncometabolites that are sufficient to drive malignant
transformation in some models [30]. Mechanistically, all three have the capacity to
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interfere with the availability of -KG as a substrate for enzymes that methylate DNA and
histones, resulting in the expression of oncogenic transcriptional programs [31, 32].

Mitochondrial Metabolism Essential for Tumor Progression
For the majority of cancers, including those that are relatively glycolytic,
mitochondrial function is not impaired [33]. Early evidence challenging the notion of
dysfunctional mitochondria in cancer came from the observation that intact tumor cells
had comparable capacity to oxidize glucose, lactic acid, and palmitic acid to that of normal
tissues [34]. Likewise, the tricarboxylic acid (TCA) cycle components from the tumor cells
exhibited normal enzymatic activities [35]. However, tumor dependency on mitochondrial
metabolism was not fully appreciated until experimental approaches to deplete mtDNA
were applied to cancer models. In vitro studies demonstrated that the consequent
OXPHOS deficiency from mtDNA depletion impairs the ability of cancer cells to grow in
an anchorage-independent manner and increases their sensitivity to cytotoxic drugs [36,
37]. Consistent with those studies, cancer cells with depleted mtDNA were only able to
generate tumors in mice once respiratory activity was restored through horizontal transfer
of host mitochondria [38]. Likewise, disrupting mitochondrial function by inactivation of
TFAM, a key activator of mitochondrial transcription and mtDNA replication, also impairs
tumorigenesis in a KRAS-driven mouse model of lung cancer [39]. Together, these
findings represent a compelling body of evidence suggesting that mitochondrial function
is essential for tumorigenesis.
The current consensus in the field of cancer metabolism is that most tumors
maintain high glycolytic rates concomitantly with OXPHOS to support the bioenergetic and
biosynthetic demands of unabated growth [40]. Increased glucose metabolism is a
consequence of activated oncogenes such as c-Myc, KRAS, and mTOR, which allow for
the generation of glycolytic intermediates that can be diverted into the pentose phosphate
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pathway for NADPH and nucleotide production [41]. Consequently, many tumors exhibit
addiction to glucose. However, oncogenes also directly regulate mitochondrial metabolism
for the purpose of generating ATP and TCA cycle intermediates required for biosynthetic
building blocks, such as oxaloacetate for nucleotide synthesis and citrate for lipid
synthesis [40]. Because glucose flux through mitochondria is limited, cancer cells turn to
alternative means to fuel the TCA cycle, including glutaminolysis and fatty acid oxidation
(FAO). As a result, many tumors can also exhibit addiction to glutamine and fatty acids
[42, 43].
In order to replenish TCA cycle intermediates that are siphoned off for biosynthetic
reactions, cancer cells depend on two major anaplerotic pathways: glutaminolysis and
pyruvate carboxylation. Glutamine is the most abundant amino acid in the body and is the
preferred anaplerotic substrate in many cancers [44]. Following uptake, glutamine is
imported into the mitochondria where it can undergo deamidation by glutaminase (GLS)
to yield glutamate, an important precursor for most non-essential amino acids. Glutamate
is then converted to α-ketoglutarate by glutamate dehydrogenase (GDH) and can proceed
through the TCA cycle. This series of biochemical reactions, termed glutaminolysis, has
been shown to contribute up to 90 percent of the oxaloacetate pool in proliferating
glioblastoma cells [45]. Consequently, glutamine deprivation can lead to the depletion of
TCA cycle intermediates and growth inhibition [46]. Addiction to glutamine is frequently
observed in many tumor types, including those of the kidney, liver, breast (basal but not
luminal), prostate, and pancreas [47].
Recent studies have demonstrated that glutamine can also be routed through the
TCA cycle in the reverse direction [48]. Following entry into the TCA cycle, glutaminederived α-ketoglutarate can undergo reductive carboxylation by IDH 1 and IDH 2 to
produce isocitrate, which can be converted to citrate by the reverse reaction of aconitase.
Adequate production of citrate is particularly important for cancer cells because it is an
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essential precursor for de novo lipogenesis [49, 50]. Evidence suggests that this pathway
is the dominant mode of glutamine metabolism in malignant cells with compromised
mitochondrial function, such as those containing mutations in mtDNA and in patientderived renal carcinoma cells with mutations in FH [48]. Reductive carboxylation has also
been shown to support anchorage-independent tumor growth in spheroid cultures through
ROS mitigation and redox homeostasis.
The second major anaplerotic pathway is the alternate conversion of pyruvate to
oxaloacetate via pyruvate carboxylase (PC), a biotin-dependent mitochondrial enzyme
[51]. While glutaminolysis has long been known have an important role in cancer
metabolism, recent evidence now suggests that PC is as crucial, if not more so, in certain
cancers, depending on the genetics and metabolic conditions. Isotope labeling studies
have indicated that PC is the predominant route of anaplerosis in non-small cell lung
cancer [52]. Neuroendocrine tumors and renal cell carcinomas with mutations in SDH
have also been shown to overexpress PC and rely on this pathway to generate
oxaloacetate for aspartate synthesis [53]. Furthermore, induction of PC was revealed as
a compensatory anaplerotic mechanism in glioblastoma cells that were deprived of
glutamine [54].
In addition to glucose and glutamine, fatty acids can also be utilized by cancer cells
to fuel the TCA cycle and the electron transport chain (ETC). In fact, certain cancer types
including diffuse large B-cell lymphoma and leukemias have been shown to primarily rely
on fatty acid oxidation (FAO) for ATP production [55, 56]. Dependence on FAO is further
heightened by metabolic stress, as experienced by tumors under nutrient- and oxygendeficient conditions [57]. Likewise, a metabolic switch to FAO was shown to be a crucial
survival mechanism for breast cancer cells following detachment from the extracellular
matrix [58]. A rate-limiting step in FAO is the formation of acyl carnitines, which is
catalyzed by carnitine palmitoyl transferase I (CPT1). This step is required for the transfer
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of long-chain fatty acids into the mitochondrial matrix, where they can undergo catabolic
processes to yield acetyl-CoA and reducing agents that fuel the TCA cycle. A major
activator of CPT1 is AMP-activated protein kinase (AMPK) [59]. Upon sensing metabolic
stress, AMPK activates FAO through phosphorylation and inhibition of acetyl-CoA
carboxylase 2 (ACC2), whose product malonyl-CoA allosterically inhibits CPT1. The
importance of CPT1 is evidenced by its upregulation in certain cancers, as well as the
finding that its pharmacological inhibition can suppresses tumor growth under metabolic
stress [60].

Targeting Mitochondria for Cancer Therapy
Mitochondria represent a promising target for cancer therapy. Several approaches
to disrupt mitochondrial function in cancer are currently under investigation in preclinical
and clinical studies. One strategy that is increasingly being recognized as a viable option
is OXPHOS inhibition [61]. While cancer cells can compensate for the loss of ATP
production through aerobic glycolysis, the rationale behind targeting mitochondrial
bioenergetics is that it limits metabolic flexibility. Many solid tumors exhibit regions that
are poorly perfused, resulting in microenvironments that are hypoxic but also nutrientpoor. In particular, tumor glucose concentrations have been reported to be up to 10-fold
lower than in surrounding normal tissues [62]. Under those glucose-limiting conditions,
aerobic glycolysis alone would not be able to supply the ATP requirements for maintaining
growth and survival. The electron transport chain, however, has been reported to function
at optimal levels even at oxygen concentrations as low as 0.5 percent [63]. In a RNAi
screen to determine the metabolic dependency of cancer cells chronically exposed to low
glucose environment, components of OXPHOS were found to be the most important for
survival [64]. Additionally, interest in the use of OXPHOS inhibitors has been significantly
fueled by the prospect of repurposing a widely prescribed medication for type II diabetes,
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metformin [65]. Numerous preclinical studies have demonstrated that metformin impairs
cancer cell proliferation and growth of diverse tumor types [66-68]. While the precise
mechanism of metformin’s antitumor effects has been debated, many recent studies have
confirmed mitochondrial complex I as a direct target for this drug [69, 70].
Considering the integral role of mitochondria in the biosynthetic processes of tumor
growth, disrupting TCA cycle metabolism represents another promising therapeutic
approach. As mentioned previously, many cancers exhibit addiction to glutaminolysis for
its contribution to TCA cycle anaplerosis. Indeed, targeting glutamine catabolism using
GLS inhibitors has been shown to disturb TCA cycling and delay tumor growth in several
experimental models of cancer [71, 72]. Furthermore, a recently developed GLS inhibitor,
CB-839, was found to have a favorable pharmacodynamic prolife by specifically targeting
GLS isoforms that are selectively expressed in tumors [73]. CB-839 is currently being
investigated in several Phase I/II clinical trials for treatment of advanced solid tumors and
hematological malignancies. It’s important to note, however, that not all tumors depend on
glutamine catabolism to fuel the TCA cycle. As an alternative approach, the direct
targeting of TCA cycle enzymes is also under clinical investigation. CPI-613 is a first-inclass small molecule lipoate derivative that inhibits two different TCA cycle enzymes,
pyruvate dehydrogenase (PDH) and -ketoglutarate dehydrogenase (KGDH) [74, 75].
The inhibition of both PDH and KGDH effectively blocks the points of entry for carbons
derived from glucose and glutamine, respectively. In a recently published Phase I clinical
trial for metastatic pancreatic cancer, the combination of FOLFIRINOX and CPI-613 was
shown to be well tolerated and reported promising to have clinical responses (61 percent
objective response rate including a 17 percent complete response rate) [76].
Indirect strategies to disrupt mitochondrial bioenergetic and biosynthetic functions
may also be a promising approach to specially target cancer metabolism. An example of
this is the use of drugs that modulate mitochondrial morphology. Mitochondria are dynamic
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organelles that undergo fission and fusion, regulated by Drp1 and Mfn1/2 respectively.
Disruption of these processes has a direct effect on mitochondrial morphology and
function [77]. Many cancers often exhibit fragmented mitochondria due to enhanced
dynamin-related protein 1 (Drp1) activity and/or downregulation of mitofusin 2 (Mfn2) [78].
This may partly reflect the need for cancer cells to generate enough mitochondria for
distribution during proliferation. While drugs that modulate mitochondrial dynamics are not
currently in clinical trials, they have shown some promise in the pre-clinical setting.
Mitochondrial division inhibitor 1 (mdivi-1) is a selective inhibitor of Drp1 that has been
shown to induce hyperfused mitochondria and suppress cell cycle progression [79].
Recently, leflunomide, which is FDA approved for rheumatoid arthritis, was demonstrated
to suppress pancreatic cancer growth by enhancing the expression of Mfn2 and thereby
promoting mitochondrial fusion [80].
As is the case with all cancer therapies, the success of mitochondria-targeting
agents will depend on whether or not toxicities can be limited. This can be particularly
challenging given the importance of mitochondrial function in most normal tissue. Through
a better understanding of the basic biology of mitochondrial metabolism in regulating
tumorigenesis, refined strategies that improve cancer specificity will have to be developed
for the therapeutic potential of mitochondria-targeting agents to be fully realized. To those
ends, the following section will review the role of a mitochondrial-specific lipid, cardiolipin,
and discuss its biosynthesis as a potentially novel target for cancer therapy.
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Cardiolipin in Mitochondrial Function and Disease: Implications
for Cancer Therapy
Cardiolipin is a unique phospholipid found almost exclusively in the mitochondria
where it constitutes approximately 20 percent of the total lipids [81]. While cardiolipin is
mostly localized to the inner mitochondrial membrane, it can also be detected on the outer
membrane upon mitochondrial stress where it mediates signaling events that lead to
mitophagy and apoptosis [82]. Through its structural and functional support of protein
complexes, cardiolipin is intimately involved in several mitochondrial processes. Given
that mitochondria play a key role in oncogenesis, cardiolipin represents an attractive yet
unexploited target for modulating mitochondrial function in cancer. This review will
summarize the major properties and functions of cardiolipin while presenting evidence that
highlight its relevance to cancer biology.

Structure and Metabolism
Cardiolipin is composed of a glycerol head group esterified to two phosphatidic
acids. While the resulting four fatty acyl chains can differ in length and saturation, linoleic
acid (18:2) is the predominant form in most animal tissues [83]. Nonetheless, there are
some tissue-specific variations. For instance, cardiolipin of the testis are composed mainly
of palmitic acid (16:0) [84], while cardiolipin of the central nervous system includes a wide
array of fatty acids, including palmitic, stearic (18:0), oleic (18:1), arachidonic (20:4) and
docosahexaenoic (22:6) acids [85]. The functional implication of different acyl chain
compositions is currently unknown and warrants further investigation.
In mammalian cells, the de novo synthesis of cardiolipin occurs on the matrix side
of the inner mitochondrial membrane following the import of phosphatidic acid (PA) from
the endoplasmic reticulum [86]. Activation of PA into CDP-diacylglycerol (CDP-DAG) is
carried out by the phosphatidate cytidylyltransferase TAM41 [87]. Phosphatidylglycerol
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phosphate synthase (PGS1) then catalyzes the committed step by converting CDP-DAG
into phosphatidylglycerol phosphate (PGP) [88]. Dephosphorylation of PGP into
phosphatidylglycerol (PG) is performed by a mitochondrial phosphatase, recently
identified as PTPMT1 [89]. Lastly, PG is combined with a second CDP-DAG molecule by
cardiolipin synthase (CRLS1) to generate immature cardiolipin [90]. The cardiolipin
biosynthesis pathway is illustrated in Figure 1.2A.
After its initial synthesis, cardiolipin undergoes several remodeling steps to
become fully functional (Fig 1.2B). This process is initiated by phospholipase A2, which
cleaves an acyl chain to generate monolyso-cardiolipin (MLCL) [91]. Subsequent
reacylation occurs through the actions of acyl-CoA:lysocardiolipin acyltransferase 1
(ALCAT1) [92], monolyso-cardiolipin acyltransferase 1 (MLCLAT1) [93], and tafazzin
(TAZ) [94]. ALCAT1 and MLCLAT1 are transferase enzymes that utilize acyl-CoA as
donors while TAZ catalyzes the removal of acyl chains from other phospholipids for
reacylation of MLCL. An unresolved issue regarding the mechanism of remodeling is the
specificity of fatty acid incorporation into cardiolipin. TAZ is a promiscuous enzyme that
does not have any intrinsic acyl specificity [95]. It is therefore unclear what process drives
the specific composition of cardiolipin.
Following synthesis and remodeling, cardiolipin becomes very stable and is
relatively protected from degradation. In fact, the half-life of cardiolipin is reported to be
several-fold longer than that of other phospholipids [96]. Isotope labeling studies in
drosophila have also demonstrated no measurable turnover in cardiolipin over a span of
at least 9 days [97]. This stability is in part due to its interaction with protein complexes,
which promotes mutual protection from degradation [97]. Nevertheless, cardiolipin is
susceptible to peroxidation due to reactive oxygen species (ROS). The peroxidation of
cardiolipin is implicated as an important trigger for mitophagy and apoptosis [98]. HSD10
was recently identified as a phospholipase that mediates the degradation of oxidized
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cardiolipin as a means of preventing apoptosis [99]. Overexpression of HSD10 has been
shown to increase pheochromocytoma growth and resistance to cell death [100].
Ultimately, the combination of increased ROS that likely increases the turnover of
cardiolipin in cancer, and the minimal rates of synthesis observed in most differentiated
cells, provides a potential therapeutic window for targeting cardiolipin biosynthesis.

Biological Function of Cardiolipin
The distinct structure of cardiolipin imparts properties that are of particular
importance to mitochondria. The bonding of two phosphatidyl moieties to a single glycerol
head results in a large anionic head group that promotes negative membrane curvature
and electrostatic interactions [101]. The significance of these features is likely related to
the requirement of mitochondria for extensive membrane folds that are densely packed
with protein. Accordingly, cardiolipin is implicated in many facets of mitochondrial functions
that are relevant to cancer biology, including oxidative phosphorylation, apoptosis, import
of mitochondrial proteins, and mitochondrial morphology and dynamics. While the list of
identified biological functions for cardiolipin continues to expand, most of them can be
summarized by the overarching theme of supporting protein complexes and promoting
proper membrane morphology (Fig 1.3).

Oxidative Phosphorylation
During cellular respiration, electrons are transferred through the ETC to create an
electrochemical proton gradient across the inner mitochondrial membrane. Components
of the ETC that convert energy from the electron transfer to H+-pumping include: NADHubiquinone oxidoreductase (complex I, CI), ubiquinol-cytochrome c oxidoreductase
(complex III, CIII), and cytochrome c oxidase (complex IV, CIV). While succinateubiquinone oxidoreductase (complex II, CII) does not directly take part in proton
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translocation, it does replenish the reduced ubiquinone pool necessary for ETC. The
energy stored by the resulting membrane potential is then used to synthesize ATP by ATP
synthase (complex V, CV).
Cardiolipin has been shown to associate with each of the ETC complexes. Specific
binding sites for cardiolipin to CII and CIV have been identified [102, 103]. Purified and
detergent-solubilized CIII and CIV contain several bound cardiolipin molecules that are
required for structural integrity and functional activity. Removal of bound cardiolipin with
phospholipase A2 digestion results in almost complete loss of CIV activity [104] and about
50 percent reduction for CIII [105]. Likewise, re-association with exogenously supplied
cardiolipin was sufficient to restore activity of both complexes [104, 105]. While
crystallographic studies have not established the cardiolipin binding sites on CI, functional
studies have confirmed that the ubiquinone reductase activity of CI requires cardiolipin
association [106].
In addition to supporting the activity of individual ETC complexes, cardiolipin also
participates in the assembly and stabilization of higher order structures called
supercomplexes or respirasomes [107]. In mammalian mitochondria, complexes I, III, and
IV assemble into a supercomplex at a stoichiometric ratio of 1:2:4 [108]. The importance
of supercomplex formation is that it promotes efficient transport of electrons and minimizes
ROS production [109]. In the absence of cardiolipin, the cooperative activity of CIII and
CIV is compromised [108]. The consequent alterations in supercomplex stability are
associated with reduced coupling of ATP synthesis to oxygen consumption [110].
Cardiolipin also promotes ETC efficiency by acting as a proton trap with its anionic head
group. This helps preserve the mitochondrial membrane potential and facilitates access
to protons for ATP synthase [111].
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Apoptosis
In mammalian cells, induction of apoptosis occurs through one of two main
pathways: intrinsic or extrinsic. The intrinsic pathway is activated by intracellular cues that
result in mitochondrial outer membrane permeabilization (MOMP) and the consequent
release of pro-apoptotic proteins into the cytoplasm [112]. The formation of MOMP
requires the action of the BCL-2 family members Bax/Bak, which are indirectly activated
by BH3-only proteins, such as Bid, that neutralize anti-apoptotic BCL-2 proteins [113, 114].
Following MOMP, the mitochondrial proteins that are released include cytochrome c and
SMAC (second mitochondria-derived activator of caspases), which initiate the caspase
cascade that carries out the cell death program. The extrinsic pathway is mediated by
extracellular ligands that bind to death receptors and, depending on the cell type, lead to
direct activation by caspase-8 of the executioner protease caspase-3 or converge with the
intrinsic pathway to initiate MOMP [115].
Cardiolipin has been shown to participate in multiple aspects involving
mitochondria-mediated apoptosis. On the outer surface of the inner mitochondrial
membrane (IMM), cardiolipin associates with cytochrome c through both electrostatic
interactions

and hydrogen

bonding

[116].

Selective

ROS-mediated

cardiolipin

peroxidation has been shown to trigger the detachment of cytochrome c and allow for its
release through pores in the OMM [117]. During the process of apoptosis, cardiolipin is
externalized onto the outer mitochondrial membrane (OMM), which is suggested to
facilitate the release of cytochrome c [118]. Furthermore, several studies have also
demonstrated that externalized cardiolipin is necessary for the recruitment of truncated
Bid and the activation of Bax/Bak [119-121]. Interestingly, it remains controversial
regarding the consequences of cardiolipin deficiency to apoptosis. On the one hand, loss
of cardiolipin may promote apoptosis through disruption of mitochondrial membrane
integrity and the release of cardiolipin-bound cytochrome c. On the other hand, cardiolipin
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deficiency may compromise Bax/Bak-mediated MOMP and induce resistance to
apoptosis. How modulating cardiolipin content alters susceptibility to apoptosis is an
important question that has yet to be fully addressed. Given that Bid is a substrate for
caspase-8 [122], it’s possible that cardiolipin-deficient cells may be more resistant to the
extrinsic pathway of apoptosis. At the same time, cardiolipin-deficient cells may also be
more sensitive to intrinsic stress signals that mediate apoptosis through Bid-independent
mechanisms.

Mitochondrial Protein Import
While mitochondria in humans contain approximately 1500 proteins to carry out
their numerous cellular processes, only 13 are encoded by the mitochondrial genome
[123, 124]. The vast majority of proteins are encoded by the nuclear genome, synthesized
as precursor proteins by cytosolic ribosomes, and imported into different compartments of
the organelle through at least five different pathways [125]. The classical pathway is
termed the presequence pathway and is responsible for the import of nearly all
mitochondrial matrix proteins and most inner membrane proteins [126]. In this pathway,
the presequence of precursor proteins are initially recognized by the TOM (translocase of
the outer mitochondrial membrane) complex. Upon translocation into the intermembrane
space, the TIM23 (translocase of the inner mitochondrial membrane 23) complex
transports the precursor proteins into one of two destinations, the inner membrane or the
matrix. The TIM23 complex comprises of three core components – Tim23, Tim17, and
Tim50 [123]. The addition of Tim21 allows the TOM complex to interact with respiratory
supercomplexes and release precursor proteins laterally into the inner membrane [127].
In the absence of Tim21, the TOM complex associates with PAM (presequence
translocase-associated motor) and utilizes the membrane potential for driving the
translocation of precursor proteins into the matrix [128].
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Translocation of mitochondrial proteins occurs at contact sites between the OMM
and IMM [129]. Early indications that cardiolipin may be involved in mitochondrial protein
import came from experiments demonstrating the enrichment of cardiolipin at
mitochondrial membrane contact sites [130]. Reconstitution experiments have revealed
that the TIM23 complex, a cardiolipin-rich membrane, and a membrane potential is the
minimal unit required for preprotein integration into the inner membrane [131].
Accordingly, measurable decreases in the rate of protein import have been documented
with cardiolipin-deficient mitochondria [132]. Mechanistically, cardiolipin stabilizes the
TIM23 complex by modulating the interaction between the Tim23 channel and the Tim50
receptor [133]. Cardiolipin further facilitates protein import by enhancing the ability of
Tim23 to anchor onto the OMM [134]. Additionally, cardiolipin is also known to associate
with Tim44 [135], an adaptor protein required for the recruitment of PAM to the TIM23
complex [136].

Mitochondrial Morphology and Dynamics
Mitochondrial morphology is regulated by coordinated cycles of fission and fusion
events that are together referred to as mitochondrial dynamics. Depending on the cell type
and circumstance, mitochondrial morphology can vary widely from fragmentated spherelike structures to extensive interconnected networks [137]. Mitochondrial fission is required
for generating adequate numbers of mitochondria in growing and dividing cells. It also
serves as a quality control mechanism to ensure that defective mitochondria are
segregated from the healthy mitochondrial network [138]. While the inverse process of
fusion does not appear essential for proliferation, unopposed fission leads to extensive
mitochondrial fragmentation and dysfunction [139]. Conditions of metabolic stress are
known to stimulate mitochondrial fusion, which is linked to increased OXPHOS and ATP
production [137]. Ultimately, the many functions of mitochondria are closely linked to their
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morphology, and thereby dependent on the proper balance between fission and fusion
events.
Mitochondrial fission is mediated by the Drp1, which is recruited from the cytosol
to form a ring-like structure that constricts both the OMM and IMM through its GTPase
activity [137]. Drp1 contains a variable domain, also called the B-insert, through which it
interacts with cardiolipin [140]. This interaction stimulates the GTPase activity of Drp1 by
promoting its oligomerization [141]. In a reciprocal manner, recombinant Drp1 has been
shown to induce the clustering of cardiolipin in synthetic liposomes in a GTP-dependent
manner [142]. Consequently, cardiolipin-enriched lipid domains are suggested to be the
hot spots for mitochondrial fission [142]. This would be consistent with the fact that
cardiolipin is highly enriched at contact sites between mitochondrial membranes [130].
Cardiolipin is also involved in mitochondrial fusion through its interaction with the
dynamin-like protein, optic atrophy 1 (Opa1). Mitochondrial fusion is mediated by
mitofusins (Mfn1 and Mfn2) for the outer membranes and Opa1 for the inner membranes.
Opa1 exists in two isoforms: the membrane anchored L-Opa1 and the proteolytically
cleaved S-Opa1 [143]. While L-Opa1 is the compulsory isoform for membrane fusion, an
assembly of both forms are required for maintaining a tubular mitochondrial network [144].
Similar to its relationship with Drp1, cardiolipin stimulates the GTPase activity of Opa1 by
facilitating its oligomerization [145]. A recent study presented evidence for a more direct
role of cardiolipin in mitochondrial fusion. Using recombinant L-Opa1 reconstituted into
cardiolipin-containing liposomes, interaction of L-Opa1 from one membrane with
cardiolipin from the other was demonstrated to be sufficient for inducing fusion [146].

Cardiolipin in Cancer and Other Diseases
Alterations in cardiolipin content, structure and acyl chain composition have been
described in several pathophysiological conditions, including thyroid disorders,
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Parkinson’s disease, diabetes, and aging [147]. The association with abnormal cardiolipin
metabolism is most clearly established in the etiology of Barth syndrome (BTHS), a rare
X-linked genetic disorder than can present with cardiomyopathy, muscle weakness,
neutropenia, and growth retardation [148]. BTHS is caused by mutations in the Tafazzin
(TAZ) gene, which results in defective cardiolipin remodeling. Lipidomic analyses have
confirmed that tissue from BTHS patients exhibit decreased cardiolipin content and
accumulation of MLCL species, which are intermediates in cardiolipin remodeling [149]. A
recent study further demonstrated that the altered cardiolipin species in TAZ-deficient cells
have compromised ability to associate with respiratory supercomplexes and become
readily degraded [97]. As a consequence, muscle tissue from BTHS patients exhibits
impaired oxygen utilization and increased fatigue [150].
Emerging evidence suggests that altered cardiolipin metabolism may also be
involved in cancer development. Cardiolipin abnormalities observed in mitochondria of
mouse brain tumor have been suggested as evidence supporting the Warburg theory of
cancer [151]. Lipidomic analysis of mitochondria isolated from implanted brain tumors
showed not only a decrease in cardiolipin content but also alterations in their fatty acid
compositions. Cardiolipin from the tumors contained predominantly shorter chain
saturated or monounsaturated FAs, indicative of immature cardiolipin. Though a direct
causation was not established, the cardiolipin abnormalities were associated with reduced
ETC activities in the brain tumors. Similarly, brain mitochondria from a strain of mice,
VM/Dk, which have a high propensity for developing spontaneous glioma also
demonstrated altered cardiolipin composition along with reduced ETC activities compared
to the brain mitochondria from B6 mice [152]. The authors of these studies suggested that
altered cardiolipin content and composition may serve as the structural basis for impaired
mitochondrial function associated with cancer. However, the increased presence of
immature cardiolipin can alternatively be interpreted as cancer cells having increased
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turnover and biosynthesis of cardiolipin. Due to replicative cell division and higher levels
of ROS that damage cardiolipin, it stands to reason that cancer cells would have an
increased demand for newly synthesized cardiolipin.
While the reports are limited, evidence suggest that oncogenic signaling pathways
upregulate cardiolipin biosynthesis. In a colon cancer cell line heterozygous for the KRAS
mutation, targeted disruption of the oncogenic allele was shown to decrease cardiolipin
levels and mitochondrial respiration [153]. Likewise, Tet-activation of mutant KRAS in lung
adenocarcinoma upregulated PGS1, the rate-limiting enzyme in cardiolipin biosynthesis,
and increased the levels of the cardiolipin precursor, PG [154]. Lymphomas induced by cMyc overexpression have also been shown to harbor increased levels of cardiolipin and
its precursor lipids [155]. As a key activator of mitochondrial biogenesis, c-Myc regulates
hundreds of nuclear-encoded mitochondrial genes as a means to increase cellular
biosynthetic and respiratory capacity required for rapid proliferation [40]. Given that
cardiolipin is necessary for mitochondrial function, it’s likely that oncogenic signals
coordinate increased mitochondrial biogenesis with cardiolipin biosynthesis. In line with
this notion, dysregulation of the mTOR signaling pathway, which also controls
mitochondrial activity and biogenesis [156, 157], has recently been documented to
upregulate a lipogenic program that includes increased cardiolipin biosynthesis [158].
Overall, these results suggest that future investigations into modulating cardiolipin
metabolism as a potential strategy for cancer therapy are warranted.
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Figure 1.1 Cardiolipin Metabolism
(A) The de novo biosynthesis pathway for cardiolipin. Indicated reactions occur in the IMM
following the import of phosphatidic acid. (B) Upon initial synthesis, cardiolipin undergoes
several remodeling steps mediated by the acyltransferases ALCAT1, MLCLAT1, or TAZ.
ALCAT1 and MLCLAT1 acylate MLCL using acyl-CoA as donors while TAZ catalyzes the
removal of acyl chains from other phospholipids, such as PC and PE, for acylation of
MLCL. CDP-DAG, CDP-diacylglycerol; CL, cardiolipin; FFA, free fatty acid; G3P, glycerol3-phosphate;

MLCL,

monolyso-cardiolipin;

PA,

phosphatidic

acid;

PC,

phosphatidylcholine; PE, phosphatidylethanolamine; PG, phosphatidylglycerol; PGP,
phosphatidylglycerol phosphate; Pi, inorganic phosphate; PLA2, phospholipase A2; PPi,
inorganic pyrophosphate.
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Figure 1.2 Schematic illustration depicting the general function of cardiolipin
The inverted conical geometry of cardiolipin promotes cristae ultrastructure and protein
interactions by providing negative curvature of the IMM – top. Depletion of cardiolipin is
associated with abnormal cristae formation and destabilized protein complexes, which can
cause disrupt mitochondrial activities such as oxidative phosphorylation – bottom.
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Figure 1.2
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Statement of Research
Mitochondria have an important role in cancer progression by conferring to cancer
cells the metabolic flexibility to survive and grow in the face of adverse environmental
conditions. Hypoxia and acidosis are well-recognized properties of the tumor
microenvironment. While hypoxia-mediated changes in cancer metabolism are well
documented, relatively little is understood regarding the metabolic adaptations that occur
in response to low extracellular pH and how they support malignant properties. In the first
part of this dissertation, we elucidate the metabolic alterations that occur in response to
acidic conditions with the hypothesis that this will reveal potential vulnerabilities that can
be exploited for therapeutic purposes. In the second part of this dissertation, we explore
cardiolipin metabolism as a novel therapeutic outlet for modulating mitochondrial
metabolism in cancer. We hypothesize that disrupting cardiolipin biosynthesis through
PTPMT1 inhibition may be an effective means to impair bioenergetic and biosynthetic
processes required for tumor progression. Together, the studies presented in this
dissertation extend the increasing body of work that highlight the importance of
mitochondrial metabolism in cancer biology and offer new insight into potential therapeutic
avenues.
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Chapter II: Invasive Phenotype Induced by Low
Extracellular pH Requires MitochondriaDependent Metabolic Flexibility
This work is published in Biochemical and Biophysical Research Communications and is
available ahead of print: https://doi.org/10.1016/j.bbrc.2020.02.018
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Highlights
•

Low pHe induces EMT and a metabolic shift away from aerobic glycolysis

•

Invasive phenotype under acidic conditions require mitochondrial metabolism

•

Etomoxir, an FAO inhibitor, specifically inhibits growth and invasion under low pHe
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Introduction
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease with the
highest mortality rate among all major cancers [1]. PDAC features an unusually intense
desmoplastic reaction that fosters a nutrient-deficient, hypoxic and acidic tumor
microenvironment [159]. Recognized as a hallmark of most solid tumors, hypoxia
profoundly influences metabolic reprogramming of cancer cells through HIF-induced
expression of glycolytic genes and regulates multiple facets of cancer biology including
therapy resistance, epithelial-to-mesenchymal transition (EMT) and metastasis [160, 161].
Importantly, the observed increase in glucose metabolism has led to improvements in
diagnostic imaging and the development of pharmacological inhibitors that target glycolytic
pathways [162]. Further understanding of metabolic adaptations that support tumor growth
and progression in the PDAC tumor microenvironment will likely uncover additional
vulnerabilities that may be therapeutically exploited.
Often colluding with hypoxia, though with little spatial correlation [163], is an acidic
tumor microenvironment caused by a combination of increased metabolism, low perfusion,
and inflammation. While the extracellular pH (pHe) of most normal tissues ranges between
7.2 to 7.4, many solid tumors exhibit an acidic pHe ranging from 6.5 to 6.9 [164].
Independent of hypoxia, extracellular acidosis facilitates malignant features including
EMT, chemoresistance, and immune evasion [165, 166]. While metabolic reprogramming
under hypoxia has been extensively characterized, relatively little is understood regarding
the metabolic adaptations that occur in response to acidic conditions and how they support
cancer progression. In the present study, we investigated metabolic changes and
dependencies of PDAC cells at low pHe and offer novel insight into the influence of pHe
on tumor metabolism and potential therapeutic avenues.
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Materials and Methods
Cell Culture
S2-013 is a subclone of a human pancreatic tumor cell line (SUIT-2) derived from
a liver metastasis [167]. T3M4 is a human carcinoembryonic antigen (CEA)-producing cell
line established from a primary PDAC transplanted into nude mice [168]. Both S2-013 and
T3M4 cells were validated through STR profiling by the Molecular Diagnostics Laboratory
at UNMC. Capan-2 cells were purchased directly from American Type Culture Collection
(ATCC). All parental lines were maintained in Dulbecco’s Modified Eagle Medium (DMEM)
containing high glucose and L-glutamine, supplemented with 10% fetal bovine serum
(FBS), at 37°C and 5% CO2. To generate  cells, which are depleted of mitochondrial
DNA, parental lines were cultured in 50ng/mL ethidium bromide, 100mM sodium pyruvate,
and 5g/mL uridine for at least one month. For establishing the experimental pH
conditions, bicarbonate concentration in DMEM was manipulated according to
calculations based on the Henderson-Hasselbalch equation for maintaining a pH of 7.4
(3.7g/L), 6.8 (0.93g/L), or 6.4 (0.37g/L) at 10% CO2; final pH was confirmed using a pH
meter. For glucose-starvation, DMEM without glucose was supplemented with 1x
glutaMAX and 10% dialyzed FBS.

In vitro Growth Assay
Cell growth was assayed using methylene blue as previously described [169].
Briefly, viable cells were seeded and cultured in 96-well plates in replicates of four. After
each time point, plates were fixed with 10% formalin and stained with methylene blue (1%
w:v in 0.01M borate buffer pH 8.4). Excess dye was completely removed through
extensive washing with borate buffer. Dye was solubilized using 0.1M HCl/Ethanol (1:1)
and absorbance was measured at 650nm using a microplate reader. Relative growth was
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calculated based on the absorbance measurements of the first time point.

Immunoblotting
Whole cell lysates following 24 hour incubation in pH-manipulated media were
prepared using RIPA buffer (1% sodium deoxycholate, 0.15 M NaCl, 0.1% SDS, 1% (v/v)
Triton X-100, 0.05 M Tris HCl, pH 7.4) supplemented with 1x Halt Protease and
Phosphatase Inhibitor Cocktail (Thermo Fisher Scientific, Waltham, MA, USA). Protein
concentrations was determined by Pierce BCA protein assay (Thermo Fisher Scientific).
Equal amounts of total protein were resolved on 4-20% SDS-PAGE gels (Bio‐Rad,
Hercules, CA, USA) and transferred to polyvinylidene difluoride (PVDF) membranes
(Millipore, Burlington, MA, USA), which were blocked with 5% bovine serum albumin
(BSA) and incubated with primary antibodies (Table 2.1) overnight at 4 °C. Following
incubation with HRP‐conjugated secondary antibodies, the antigen‐antibody complex was
developed using Bio‐Rad enhanced chemiluminescence (ECL) Prime Western Blotting
detection reagent (GE Life Sciences, Pittsburgh, PA, USA).

Invasion Assay
Relative invasion was determined using 24-well Matrigel invasion chambers with
8 m PET membranes (Corning, Corning, NY, USA). Inserts were rehydrated in serumfree medium per manufacturer’s instructions. Complete medium (pH 7.4, 6.8, or 6.4) was
used as chemoattractant. Suspensions of 5 x 104 cells in 500 L of serum-free medium
(pH 7.4, 6.8, or 6.4) were added into the chambers and incubated for 22 hours at 37°C in
10% CO2. For FAO inhibition,100M etomoxir was added into the chambers. Non-invading
cells were removed with a cotton swab while invaded cells were fixed in formalin and
stained with methylene blue. Images were captured using an EVOS Cell Imaging System
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(Thermo Fisher Scientific, Waltham, Massachusetts, USA) at 10x magnification.
Quantification was performed by solubilizing the dye with 0.1M HCl/Ethanol (1:1) and
measuring absorbance at 650nm.

Metabolic Flux Assays
Oxygen consumption rates (OCR) and extracellular acidification rates (ECAR) of
live cells were measured in real-time using the Seahorse XFe96 Analyzer (Agilent, Santa
Clara, CA, USA). Cells were pre-incubated at pH 7.4, 6.8, or 6.4 for 24 hours and then
seeded at a concentration of 2 x105 (S2-013), 3 x105 (Capan-2), or 3 x105 (T3M4) cells
per well in 96-well assay plates and allowed to attach overnight. For glycolysis stress test,
culture medium was replaced with Seahorse XF DMEM (Agilent) supplemented with 2mM
glutamine, pH 7.4 one hour prior to the assay. Measurements were taken before and after
each sequential treatment with glucose (10mM), oligomycin (1M), and 2-DG (50 mM).
For the mitochondrial stress test, culture medium was replaced with Seahorse XF DMEM
supplemented with 10mM glucose, 1mM sodium pyruvate, and 2mM glutamine, pH 7.4
one hour prior to the assay. Cells were sequentially treated with oligomycin (1M), FCCP
(1M), and rotenone (0.5M). For determining FAO and glutamine-dependent OCR,
culture medium was replaced with unbuffered DMEM, which was pH adjusted with 1N
HCL or 1N NaOH to 7.4, 6.8, or 6.4 and supplemented with 2% FBS and 2mM glutamine,
one hour prior to the assay. Following basal measurements, cells were treated with either
etomoxir (50M) or CB-839 (2M). FAO and glutamine-dependent OCR were determined
as the loss of OCR following etomoxir or CB-839 injection. All measurements were
normalized to total protein as determined by BCA assay.
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Glucose Uptake Measurements
Cells were seeded in a 96-well plate and incubated at pH 7.4, 6.8, or 6.4 for 24
hours. Uptake of glucose was determined using Glucose Uptake-Glo Assay (Promega,
Madison, WI, USA) per manufacturer’s instructions.

Cell Viability Assays
Cells were pre-incubated at pH 7.4, 6.8, or 6.4 for 24 hours and then starved of
glucose for the indicated time points or treated with the following metabolic inhibitors:
etomoxir (50M) (Sigma-Aldrich, St Louis, MO, USA), CB-839 (2M) (Selleckchem,
Houston, TX, USA), oligomycin (1M) (Sigma-Aldrich), or 2-deoxy-D-glucose (2-DG)
(20mM) (Sigma-Aldrich) for 48 hours. Cell viability was determined by adding alamarBlue
(Bio-Rad) in an amount equal to 10% of the volume in the well and incubating for 2 hours.
Fluorescence (560ex/590em) was measured using a microplate reader. Relative viability
was calculated based on the fluorescence intensity of the untreated or control wells.

PCR Determination of mtDNA Copy Number
Mitochondrial DNA content, relative to nuclear DNA, was quantified using real-time
PCR analysis as previously described [170]. Briefly, total DNA was extracted using the
DNeasy Blood and Tissue Kit (Qiagen, Hilden, Germany) according to the manufacturer’s
instructions. RT-PCR was performed using PowerUp SYBR Green Master Mix (Applied
Biosystems, Foster City, CA, USA). The primer sets for mtDNA and nucDNA are listed in
Table 2.2. Mitochondrial DNA copy number was determined by the following equation: 2
x 2CT where CT = (nucDNA CT – mtDNA CT).
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Lipid Uptake Assay
Fluorescently labeled palmitate, BODIPY C16 (Invitrogen, Carlsbad, CA, USA),
was prepared as a 5mM solution in DMSO. Lipids were diluted in serum-free media without
glucose and incubated at a 6:1 molar ratio with defatted BSA (GoldBio, St Louis, MO,
USA) for 1 hour at 37°C to allow for conjugation. Cells were seeded in a 96-well plate and
incubated at pH 7.4, 6.8, or 6.4 for 24 hours. One hour prior to lipid exposure, culture
media was replaced with serum-free media without glucose. BODIPY C16:BSA solution
was added to each well and uptake was allowed to proceed for 15 minutes. Cells were
washed with PBS and fluorescence (485ex/520em) was measured using a microplate
reader. Normalization was performed with BCA total protein quantification.

Statistical Analysis
Statistical significance of differences between mean values was assessed using
an unpaired, two-sided t-test. Differences were considered significant at P < 0.05. Unless
indicated otherwise, data are shown as mean ± SD. Statistical analyses are reported for
biological replicates.

37

Results
Acidic conditions drive an EMT phenotype associated with reduced glucose
metabolism
To investigate the influence of acidosis on proliferation, PDAC cells were exposed
to three different pH conditions – 7.4, 6.8, or 6.4. Compared to normal conditions, low
extracellular pH negatively affected the growth rates in vitro (Fig 2.1A). While cells
maintained the ability to proliferate at pH 6.8, little to no measurable growth was observed
at pH 6.4. Accompanying the impaired growth were morphological changes, specifically
from epithelial-like to mesenchymal. Previous studies have demonstrated that low
extracellular pH can promote EMT-associated phenotypes, such as invasion and
metastasis [171]. Consistent with those findings, we observed the induction of EMT by
extracellular acidification as evidenced by increased expression of N-cadherin and
decreased expression of E-cadherin (Fig 2.1B). Likewise, invasion was significantly
increased at pH 6.8 in all three PDAC cell lines (Fig 2.1C and 2.1D). Interestingly, this
phenotype was abrogated upon further media acidification to pH 6.4.
Although metabolic reprogramming linked to EMT at normal pH is typically
characterized by increased aerobic glycolysis [172, 173], we found that acidosis-induced
EMT was instead accompanied by a decrease in glycolysis as measured by a Seahorse
Extracellular Flux assay (Fig 2.2A). The parameters determined from glycolytic stress
tests showed significant reduction in both glycolysis and glycolytic capacity (Fig 2.2B). To
investigate whether the observed decrease in extracellular acidification rate (ECAR) was
due to glucose flux being diverted to oxidative phosphorylation or resulted from a reduction
in overall glucose utilization, a luminescent glucose uptake assay was performed.
Supporting the latter hypothesis, a significant decrease in glucose uptake was observed
with exposure to acidic stress (Fig 2.3A). Furthermore, consistent with reduced

38

dependency on glucose metabolism, PDAC cells under acidic conditions exhibited
increased levels of resistance to glucose starvation (Fig 2.3B).

Increased invasion mediated by extracellular acidification requires oxidative
phosphorylation
Given the observed decrease in glucose metabolism, we investigated the effects
of media acidification on mitochondrial metabolism. Using a Seahorse mitochondrial
stress test, we found that exposure to low extracellular pH did not drastically alter overall
oxygen consumption rate (OCR) profiles (Fig 2.4A). While no conclusive change was
determined in basal respiration, the maximal respiration and reserve capacity (Fig 2.4B)
were elevated. Notably, the OCR to ECAR ratio was significantly increased with media
acidification, implying a metabolic shift in dependency from aerobic glycolysis to oxidative
phosphorylation (OXPHOS) (Fig 2.4B).
To further examine OXPHOS dependency under acidic conditions, cancer cells
with depleted mitochondrial DNA () were generated using low dose ethidium bromide.
Loss of mitochondrial DNA copy number was confirmed through qPCR analysis (Fig
2.5A). As expected, the  cells had no detectable levels of oxygen consumption (Fig
2.5B). Rather, these cells relied heavily on glycolysis and demonstrated relatively high
levels of ECAR. However, resembling the parental lines,  cells also exhibited reduced
glycolysis in response to acidic stress (Fig 2.5C). The exceptionally low levels of ECAR
detected at pH 6.4 was partially due to loss of viability, as  cells were less tolerant of
media acidification. To test whether resistance to glucose starvation under acidic
conditions was dependent on OXPHOS, we measured the viability of  cells in the
absence of glucose. We found that irrespective of pH,  PDAC cells no longer survived
without glucose (Fig 2.6A). Furthermore, unlike their parental counterparts,  cells did
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not exhibit increased invasion at low extracellular pH (Fig 2.6A and 2.6B). Altogether,
these results suggested that under low extracellular pH, PDAC cells require the ability to
shift their dependency from aerobic glycolysis in order to support the invasive phenotype.

Fatty acid oxidation specifically supports cell viability and invasion of PDAC cells
under low extracellular pH
Consistent with increased OXPHOS dependency, extracellular acidification
increased the sensitivity of PDAC cells to oligomycin, an ATP synthase inhibitor (Fig 2.7).
To determine the major fuel source for mitochondrial metabolism under low extracellular
pH, PDAC cells were treated with metabolic inhibitors of glucose, glutamine, or long-chain
fatty acid oxidation (FAO) pathways using 2-deoxyglucose (2-DG), CB-839, and etomoxir,
respectively. Only treatment with etomoxir mirrored the effects observed with OXPHOS
inhibition, suggesting a metabolic shift in dependency from glucose to fatty acids (Fig
2.8A). An increase in FAO-dependent OCR was also confirmed with a Seahorse assay
(Fig. 3B). This was in contrast to glutamine-dependent OCR which was unaffected by
extracellular acidification (Fig 2.8B). Furthermore, PDAC cells exhibited increased lipid
uptake under acidic culture conditions, as measured by incubating the cells with
fluorescently labelled palmitate (BODIPY C16) (Fig 2.8C). Finally, we tested whether
blocking FAO with etomoxir could inhibit invasion at pH 6.8. Similar to what was observed
in respiratory-deficient cells, treatment with etomoxir effectively prevented low pH-induced
invasion (Fig 2.9A and 2.9B).
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Discussion
Despite substantial progress in overall cancer treatment, PDAC remains a disease
with poor prognosis and limited therapeutic options. While targeted therapy represents a
promising strategy, KRAS mutations, the primary driver in up to 90 percent of PDAC
patients, are currently undruggable [17]. Alternative approaches have focused on
exploiting KRAS-regulated metabolic pathways, such as enhanced aerobic glycolysis
[174]. The genetic factors that influence tumor metabolism are relatively well understood;
however, much of how extrinsic factors alter metabolic dependencies is unclear. This
knowledge gap may partially explain why targeting glucose metabolism has not yet
translated to clinical success [175]. Significantly, our results show that acidic conditions
can drive KRAS-mutant PDAC cell lines to shift away from aerobic glycolysis and become
resistant to glucose starvation. Thus, efforts to inhibit glycolytic metabolism may not be
effective without concurrently targeting intratumoral acidity.
Further impetus for targeting the acidic tumor compartment comes from evidence
that it drives local invasion and malignant progression [176]. Consistent with previous
studies, we observed that extracellular acidification of culture media to pH 6.8 induced
expression of EMT markers and increased invasiveness of PDAC cells. Unanticipated,
however, was that a further decrease in acidity to pH 6.4 inhibited invasion, despite
elevated EMT markers. Although further investigation is necessary, we suspect this could
be due to decreased motility from bioenergetic deficiency. As shown from our results,
glycolysis is increasingly compromised with media acidification, without an inverse
correlation in OXPHOS compensation. Furthermore, our results showed that increased
acidic conditions may have a negative effect on cell migration (Supplementary Fig.1A).
While unexpected, the uncoupling of migration and invasion during cancer-associated
EMT has been previously documented [177]. In addition, our studies demonstrated that
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exogenous ATP supplementation could increase invasion at pH 6.4 (Supplementary Fig.
1B). Thus, there is likely an optimal extracellular pH that supports increased invasion –
where an EMT phenotype is induced but the bioenergetic demands of motility are still met.
Finally, we confirmed that PDAC cells under acidic conditions increase their
dependency on mitochondrial metabolism. Notably, our study is the first to document that
OXPHOS is specifically required for low pH-mediated invasion. This finding is particularly
interesting given that several groups have reported OXPHOS deficiency to promote
invasion [22, 24, 178-180]. However, our results suggest that the phenotypic response to
OXPHOS inhibition is likely pH dependent. While reduced OXPHOS may prompt invasion
of cancer cells residing in a non-acidic environment, it significantly dampens the
invasiveness of cells under acidic stress. Furthermore, we found that low extracellular pH
enhanced uptake of exogenous lipids in PDAC cells, suggesting that fatty acids are the
predominant fuel source for mitochondrial respiration under acidic conditions. This is
similar to the results from a previous study that reported an increase in FAO, associated
with alterations in mitochondrial and histone acetylation, in cancer cells adapted to chronic
acidosis [181]. However, our results suggest that changes in fatty acid metabolism can
occur following acute (24 hours) exposure to low pH conditions, indicating that a rapid
stress response mechanism may be involved. These results are especially pertinent in
light of a recent study demonstrating that resident pancreatic stellate cells, once activated
into

cancer-associated

fibroblasts,

secrete

abundant

lipids

into

the

tumor

microenvironment [182]. Importantly, inhibiting FAO with etomoxir effectively suppressed
low pH-induced invasion without altering invasiveness at pH 7.4. Based on these results,
future studies to investigate FAO as a potential target for adjunct therapy in metastasis
prevention are warranted.
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Figure 2.1 Extracellular acidification induces EMT phenotype
(A) In vitro proliferation of PDAC cells cultured at pHe 7.4, 6.8, or 6.4 using a methylene
blue-based assay. (B) Immunoblot analysis from whole cell lysates following 24-hour
incubation at the indicated pHe conditions, with β-actin as loading control. (C)
Representative images from Matrigel invasion assays. Bar, 400m. (D) Quantification of
relative invasion (n=2). Data are shown as mean  SD. *p < 0.05; **p < 0.01

43

Figure 2.1

A

B

C

D

44

Figure 2.2 Acidic conditions suppress glycolysis
(A) Extracellular acidification rates (ECAR) measured at baseline conditions and following
sequential injections of glucose, oligomycin, and 2-DG using the Seahorse XFe96
Analyzer. (B) Parameters of the glycolytic stress test calculated from the ECAR
measurements (n=3). Data are shown as mean  SD. *p < 0.05; **p < 0.01; ***p < 0.001.
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Figure 2.3 PDAC cells demonstrate reduced glucose uptake and resistance to
glucose starvation upon acidic stress.
(A) Relative uptake of glucose measured using Promega Glucose Uptake-Glo Assay
(n=3). (B) Relative cell viability following glucose starvation compared to unstarved
controls (n=3). Data are shown as mean  SD. *p < 0.05; **p < 0.01; ***p < 0.001.
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Figure 2.3
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Figure 2.4 OXPHOS is maintained despite reduced glycolysis
(A) Oxygen consumption rates (ECAR) measured at baseline conditions and after
sequential injections of oligomycin, FCCP, and rotenone using the Seahorse XFe96
Analyzer. (B) Parameters of mitochondrial respiration calculated from the OCR
measurements (n=3). Data are shown as mean  SD. *p < 0.05; **p < 0.01; ***p < 0.001.
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Figure 2.4
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Figure 2.5 Low extracellular pH reduces glycolysis in respiration-deficient cells
(A) Quantification of mitochondrial DNA copy number through qPCR of total DNA extract
using genomic DNA as reference (n=3). (B) OCR measurements of  cells and their
parental counterparts (n=3). (C) ECAR measurements  cells pre-cultured under
indicated pHe conditions (n=3). Data are shown as mean  SD. *p < 0.05; **p < 0.01; ***p
< 0.001.
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Figure 2.5
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Figure 2.6 Mitochondrial respiration required for acidosis-induced resistance to
glucose starvation and increased invasion
(A) Relative viability of  cells following glucose starvation compared to unstarved
controls (n=3). (B) Representative images from Matrigel invasion assays with  cells. Bar,
400m. (C) Quantification of relative invasion (n=2). Data are shown as mean  SD. *p <
0.05; **p < 0.01; ***p < 0.001.
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Figure 2.7 PDAC cells under low extracellular pH exhibit increased sensitivity to
OXPHOS and FAO inhibitors
PDAC cells were pre-conditioned under the indicated extracellular pH for 24 hours and
then treated with oligomycin (1M), 2-DG (20mM), CB-839 (2M), or etomoxir (50M) .
Relative cell viability following 48-hour treatment with the metabolic inhibitors compared
to untreated controls (n=3). Data are shown as mean  SD. *p < 0.05; **p < 0.01; ***p <
0.001.
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Figure 2.7
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Figure 2.8 Acidic conditions induce fatty acid oxidation and increased lipid uptake
FAO and glutamine-dependent OCR as determined by the decrease in basal OCR
following injection of etomoxir (A) (n=3) or CB-839 (B) (n=3), respectively. (C) Lipid uptake
measured by incubating cells with fluorescently labeled palmitate (BODIPY C16)
conjugated to fatty acid-free BSA for 15 min following 24-hour pre-culturing under the
indicated pHe conditions (n=3). Data are shown as mean  SD. *p < 0.05; **p < 0.01; ***p
< 0.001.
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Figure 2.8
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Figure 2.9 Inhibition of fatty acid oxidation suppresses the increased invasion
induced by low extracellular pH
(A) Representative images from Matrigel invasion assays. Bar, 400m. PDAC cells were
incubated at the indicated pH conditions with or without etomoxir for 22 hours. (B)
Quantification of relative invasion (n=2). Data are shown as mean  SD. *p < 0.05; **p <
0.01; ***p < 0.001.

59

Figure 2.9
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Figure 2.10 Acidosis impairs migration due to bioenergetic deficiency
(A) Left – Representative images from a scratch assay. T3M4 cells were grown to
confluency on a 24-well plate. Following the creation of two perpendicular scratches, wells
were replaced with the indicated pH media. Images were taken immediately and after 24hour incubation with EVOS imaging system. Right – Area of the wound before and after
incubation was measured with ImageJ software (n=2) (B) Left – Representative images
from Matrigel invasion assays. Suspension of T3M4 cells in pH 6.4 media was added into
the inserts and incubated with and without 100M ATP. Bar, 2000m. Right Quantification of relative invasion (n=2). Data are shown as mean  SD. *p < 0.05; **p <
0.01; ***p < 0.001.
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Figure 2.10
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Table 2.1 Primary antibodies and dilutions
Antibody

Vendor

Cat. #

Dilution

E-cadherin

Abcam

Ab15148

1:1000

N-cadherin

Abcam

Ab18203

1:1000

MMP-2

CST

D4K9N

1:2000

-SMA

CST

D4M2N

1:1000

-actin

CST

8H10D10

1:5000

Table 2.2 RT-PCR primers
Genome

Target
Gene

Amplicon
(bp)

Tm

F Primer 5’-3’

R Primer 3’-5’

Mitochondrial

tRNALeu

107

62

CACCCAAGAACAGGGTTTGT

TGGCCATGGGTATGTTGTTA

Nuclear

B2Microgl
obulin

86

62

TGCTGTCTCCATGTTTGATGTATCT

TCTCTGCTCCCCACCTCTAAGT
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Chapter III: Cardiolipin Deficiency from PTPMT1
Ablation Impairs Mitochondrial Metabolism
Required for Pancreatic Cancer Growth
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Highlights
•

PTPMT1 supports PDAC growth both in vitro and in vivo

•

Impaired proliferation is associated with depleted cardiolipin levels

•

PTPMT1 ablation compromises mitochondrial membrane integrity and function

•

Inhibition of PTPMT1 increases dependency on glycolysis
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Introduction
Pancreatic ductal adenocarcinoma (PDAC) stands as the third leading cause of
cancer-related deaths in the United States and has the highest mortality rate among all
major cancers [1]. A prominent pathological feature of PDAC is the abundant stromal
compartment,

or

desmoplasia,

that

creates

a

nutrient-deprived

and

hypoxic

microenvironment [159]. Under these harsh conditions, pancreatic cancer cells rely
heavily upon mitochondrial function to sustain growth and survival [183, 184]. Contrary to
the Warburg hypothesis, most cancers, including those that are highly glycolytic, have fully
functioning mitochondria [33]. In fact, an increasing body of evidence suggests that
mitochondrial function is indispensable for tumor growth. Silencing TFAM, a key activator
of mitochondrial transcription and mtDNA replication, was shown to impair tumorigenesis
in a KRAS-driven mouse model of lung cancer [39]. Likewise, depletion of mtDNA
prevented cancer cells from generating tumors until respiratory activity was restored
through horizontal transfer of whole mitochondria from the host [38]. These and other
findings highlight the importance of mitochondria in cancer and suggest that targeting its
activity is a promising avenue for cancer therapy.
Here we investigated a novel approach for exploiting cancer cell dependence on
mitochondrial metabolism through inhibition of cardiolipin (CL) biosynthesis. CL is an
anionic phospholipid found almost exclusively in the inner mitochondrial membrane (IMM).
Its unique chemical structure consists of a glycerol head group esterified to two
phosphatidic acids, giving it a total of four fatty acyl chains. The primary function of CL is
to support activity of respiratory super-complexes [185]. Due to its negative charge, CL
also acts as a proton trap, which helps preserve mitochondrial membrane potential [111].
A growing list of other possible functions for CL include: a role in apoptosis [117];
mitochondrial dynamics and cristae formation [186]; and the import of mitochondrial
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proteins [133]. Alterations in CL content, structure and acyl chain composition have been
described in several pathophysiological conditions, such as Barth syndrome, diabetes,
nonalcoholic fatty liver disease, cardiac ischemia-reperfusion, hypo-hyperthyroidism, and
aging [147]. More recently, elevated levels of CL or its precursor lipids have been observed
in thyroid oncocytic [187], renal cell [188], and hepatocellular carcinomas [155].
Implicated in the biosynthesis of CL is PTPMT1, a dual-specificity phosphatase
that is anchored to the IMM [189]. PTPMT1 was previously identified as a promising drug
target for treatment of type II diabetes [190-192]. Recently, the physiological substrate of
PTPMT1 was determined to be phosphatidylglycerol phosphate [89]. The resulting
product, phosphatidylglycerol (PG), is both a component of pulmonary surfactant and a
precursor to CL [189]. Despite its potential role in cancer metabolism, PTPMT1 has not
been previously investigated as a target for pancreatic cancer therapy. In the present
study, we demonstrate that ablation of PTPMT1 inhibits CL biosynthesis and disrupts
mitochondrial metabolism, resulting in impaired pancreatic cancer growth.
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Materials and Methods
Cell Culture
T3M4 is a human carcinoembryonic antigen (CEA)-producing cell line established
from a primary PDAC transplanted into nude mice [168]. S2-013 is a cloned subline of a
human pancreatic tumor cell line (SUIT-2) derived from a liver metastasis [167]. Both
T3M4 and S2-013 cells were genetically verified by the Molecular Diagnostics Laboratory
at UNMC. MIA Paca-2, PANC-1, Capan-2, HPAF-II, HPNE and 293T cells
were purchased directly from American Type Culture Collection (ATCC). All cell lines were
maintained in Dulbecco’s Modified Eagle Medium containing high glucose and Lglutamine, supplemented with 10% fetal bovine serum, at 37°C and 5% CO2.

Lentivirus-mediated delivery of CRISPR/Cas9
LentiCRISPRv2 plasmids encoding sgRNAs for human PTPMT1 (sgRNA1, 5’TGGCGCGTCAAGCTCCGCAA-3’;

sgRNA2,

5’-GTTGCGGAGCTTGACGCGCC-3’;

sgRNA3, 5’- TGAACGAGGAGTACGAGACG-3’) were obtained commercially (GenScript,
Piscataway, NJ, USA). A second-generation lentivirus packaging system consisting of
psPAX2 (Addgene #12260) and pMD2.G (Addgene #12259) was used to create virus
particles carrying the transfer plasmids. Transfection of 293T cells using Lipofectamine
3000 (Invitrogen, Carlsbad, CA, USA) was performed according to the manufacturer’s
protocol. Destination cells were infected with filtered lentivirus supernatants, using 4
g/mL polybrene and low virus titer. After 48 hours, transduced cells were selected with
1-2 g/mL puromycin for 3 days. Unless otherwise stated, cells were infected with a
mixture of lentivirus carrying the three PTPMT1 sgRNAs and downstream experiments
were performed 7-14 days post infection. Loss of PTPMT1 expression was confirmed by
immunoblotting and immunofluorescence of puromycin-resistant cells. For controls, cells
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were transduced with empty lentiCRISPRv2.

Immunoblotting
Whole cell lysates were prepared using RIPA buffer (1% sodium deoxycholate,
0.15 M NaCl, 0.1% SDS, 1% (v/v) Triton X-100, 0.05 M Tris HCl, pH 7.4) supplemented
with 1x Halt Protease and Phosphatase Inhibitor Cocktail (Thermo Fisher Scientific,
Waltham, MA, USA). Protein concentrations was determined by Pierce BCA protein assay
(Thermo Fisher Scientific). Equal amounts of total protein were run on SDS-PAGE gels
and transferred to nitrocellulose membranes, which were blocked with 5% bovine serum
albumin in 0.1% TBS-Tween and incubated with primary antibodies overnight at 4 °C
(Table 3.1). LI-COR fluorescent secondary antibodies (IRDye 800CW or 680RD) were
diluted 1:10 000 and membranes were imaged using a LI-COR Odyssey Scanner.

In vitro Growth Assay
Cell growth was assayed using methylene blue as previously described [169].
Briefly, viable cells (1000 to 5000) were seeded and cultured in 96-well plates in replicates
of four. After each time point, plates were fixed with 10% formalin and stained with
methylene blue (1% w:v in 0.01M borate buffer pH 8.4). Excess dye was completely
removed through extensive washing with borate buffer. Dye was solubilized using 0.1M
HCl/Ethanol (1:1) and absorbance was measured at 650nm using a microplate reader.
Relative growth was calculated based on the absorbance measurements of the first time
point.

Colony-Forming Assay
Cells were seeded in 6-well plates at a concentration of 500 cells (S2-013) or 1000
cells (T3M4) per well. Medium was freshly added every other day for 10 days (S2-013) or
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20 days (T3M4). Plates were fixed with 10% formalin and colonies were stained with
Crystal Violet (0.2% w/v). Image analysis and quantification was performed using Fiji
(ImageJ, www.fiji.sc).

Orthotopic Tumor Study
All animals were housed and treated in accordance with institutional animal care
and use committee guidelines. S2-013 ECV and sgPTPMT1 cells (5 x 105) were injected
orthotopically into the pancreata of athymic nu/nu mice (Crl:NU-Foxn1nu) (n=5 per group),
as previously described [193]. Tumor volumes were measured weekly through ultrasound
using the Vevo 2100 imaging system (VisualSonics, Toronto, ON, Canada).

CFDA-SE Proliferation
Cells were stained with 5uM CFDA-SE (carboxyfluorescein diacetate, succinimidyl
ester) (Invitrogen) in PBS and incubated at 37C for 15 minutes. Cells were washed
thoroughly with fresh media and seeded at 2 x 105 cells/well (S2-013) or 5 x 105 cells/well
(T3M4) in 6-well plates. At each time point (overnight for initial time point), cells were
collected and fixed with 4% PFA. Stained cells were visualized with flow cytometry (492nm
ex, 517nm em).

Cell Cycle Analysis
Cells (1x106) were fixed with cold 70% ethanol and stained with Telford reagent
(0.1mM EDTA, 2.5 U/mL RNAse A, 50ug/mL Propidium Iodide, 0.1% Triton X-100, in
PBS). Staining of DNA was measured through flow cytometry and analyzed using FlowJo
Cell Cycle analysis.

Lipid Extraction and PG/CL Quantification
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Total lipids were extracted as previously described [194]. Briefly, methyl-tert-butyl
ether (MTBE) and methanol (10:3 v/v) were added to a pellet of 5 x 106 cells. Phase
separation was induced by the addition of 0.2 volume equivalents water. Following
centrifugation, the upper organic phase containing the lipids was dried in a speed vacuum
centrifuge. Samples were then analyzed for the sum of PG and CL content using a
validated enzymatic method [195, 196] available as a commercial kit (Cell Biolabs, San
Diego, CA, USA), per manufacturer’s instructions. Phosphatidylcholine (PC) 16:0-18:1
and phosphatidylserine (PS) 16:0-18:1 were obtained from Avanti Polar Lipids, Alabaster,
AL, USA (#860399 and #860403).

PCR Determination of mtDNA Copy Number
Mitochondrial DNA content, relative to nuclear DNA, was quantified using real-time
PCR analysis as previously described [170]. Briefly, total DNA was extracted using the
DNeasy Blood and Tissue Kit (Qiagen, Hilden, Germany) according to the manufacturer’s
instructions. RT-PCR was performed using PowerUp SYBR Green Master Mix (Applied
Biosystems, Foster City, CA, USA). The primer sets for mtDNA and nucDNA are listed in
Table 3.2. Mitochondrial DNA copy number was determined by the following equation: 2
x 2CT where CT = (nucDNA CT – mtDNA CT).

Transmission Electron Microscopy
Samples for TEM imaging were fixed by immersion in a solution of 2%
glutaraldehyde, 2% paraformaldehyde in a 0.1M Sorenson’s phosphate buffer (pH 7.2) for
a minimum of 24h at 4°C. Samples were then washed three times with Sorenson’s
phosphate to clear excess fixative. During processing, samples were post-fixed in a 1%
aqueous solution of osmium tetroxide for 30 minutes. Subsequently, samples were
dehydrated in a graded ethanol series (50, 70, 90, 95, 100%) and propylene oxide was
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used as a transition solvent between the ethanol and Embed 812 resin (EMS). Samples
were allowed to sit overnight in a 50:50 propylene oxide:resin solution until all the
propylene oxide had evaporated. Samples were then incubated in fresh resin for 2 hours
at room temperature before final embedding. Polymerization took place at 65°C for 24
hours. Thin sections (100nm) made with Leica UC6 Ultracut ultramicrotome were placed
on 200 mesh copper grids. Sections were stained with 2% Uranyl Acetate followed by
Reynolds Lead Citrate and examined on a Tecnai G2 Spirit TWIN (Thermo Fisher
Scientific) operating at 80kV.

OCR and ECAR Measurements
Oxygen consumption rates (OCR) and extracellular acidification rates (ECAR) of
live cells were measured in real-time using the Seahorse XFe96 Analyzer (Agilent, Santa
Clara, CA, USA). Cells were seeded at a concentration of 2 x105 (S2-013) or 3 x105
(T3M4) cells per well in 96-well assay plates and allowed to attach overnight. One hour
prior to the assay, culture medium was replaced with Seahorse XF DMEM (Agilent)
supplemented with 10mM glucose, 1mM sodium pyruvate, and 2mM glutamine, pH 7.4.
Measurements were taken before and after each sequential injection of oligomycin (1M),
FCCP (1M), and rotenone (0.5M). Readings were normalized to protein levels as
determined by BCA assay.

Mitochondrial Membrane Potential
Tetramethylrhodamine, ethyl ester (TMRE) labeling kit (Cell Signaling, Danvers,
MA, USA) was used to measure mitochondrial membrane potential. Cells (1x106) were
suspended in warm media and labeled with 200nM concentration of TMRE for 15 minutes
at 37°C. For CCCP treatment, 50M was added 15 min prior to TMRE labeling. Samples
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were washed and resuspended in PBS and were analyzed through flow cytometry

Metabolomics
Metabolites were extracted as previously described [197]. Briefly, cells were
cultured overnight and samples were harvested 2 hours after addition of fresh media. Cells
were washed with 0.9% saline and snap frozen on liquid nitrogen. Polar metabolites were
extracted with cold 80:20 mixture of LC-MS grade methanol and water (Fisher Scientific)
and dried using a speed vacuum centrifuge. Samples were dissolved in 1:1 mixture of LCMS grade methanol and equal volumes were injected for LC-MS/MS analysis. Metabolites
were separated and eluted employing Acquity H-Class UPLC system (Waters, Milford,
MA, USA) configured with BHE amide column (150 x 2.1 mm, Waters) with a gradient of
mobile phase consisting of Buffer A (100% Acetonitrile) and Buffer B (20 mM Ammonium
acetate, pH 9.0). A Xevo TQ-S Triple Quadrupole mass spectrometer (Waters) with highly
selective positive and negative modes of electron spray ionization (ESI) was used to
identify metabolic intermediates. TargetLynx (Waters) was used for data processing. Peak
areas were normalized with the respective protein concentrations and the resultant peak
areas were subjected to relative quantification analyses with MetaboAnalyst 4.0.

Cell Viability Assay
For single 2-deoxy-D-glucose (2-DG) (Sigma-Aldrich, St. Louis, MO, USA)
treatments, 10 000 (S2-013) or 20 000 cells (T3M4) were seeded on a 96-well plate
overnight in replicates of four. Fresh media containing 2-DG was added and incubated for
24 hours. Relative cell viability was determined based on the reduction of a water-soluble
tetrazolium salt, XTT (Cell Signaling). For combined alexidine dihydrochloride (SigmaAldrich) and 2-DG treatments, 5000 (S2-013), 10 000 cells (T3M4), or 15 000 cells (HPNE)
were seeded on a 96-well plate. Twenty-four hours prior to 2-DG treatment, cells were
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either incubated with 4M alexidine or equivalent volume in DMSO. To analyze the drug
interaction between alexidine and 2-DG, the coefficient of drug interaction (CDI) was
calculated as described previously [198]. CDI is defined by the following equation: (AB) /
(A x B), where A and B are ratio of the single agent group to control group and AB is the
ratio of combination group to control group. CDI values <1, = 1 or >1 indicate that the
drugs are synergistic, additive or antagonistic, respectively.

Statistical Analysis
Statistical significance of differences between mean values was assessed using
an unpaired, two-sided t-test. Differences were considered significant at P < 0.05. Unless
indicated otherwise, data are shown as mean ± SD. Statistical analyses are reported for
independently repeated experiments and not technical replicates.
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Results
PTPMT1 supports growth of pancreatic cancer cells
To investigate the role of PTPMT1 on PDAC malignant phenotype, we employed
small guide (sg)RNAs in combination with CRISPR-Cas9 to generate cancer cells lacking
a functional PTPMT1 gene. We tested three different PTPMT1 sgRNA target sequences
– each were ranked in the top 5 by the CHOPCHOP web tool for cutting efficiency and
having the least potential off-target sites (https://chopchop.cbu.uib.no). All three guides
were able to disrupt PTPMT1 expression in both T3M4 and S2-013 cells (Fig 3.1A). We
then assessed the effect of PTPMT1 depletion on the kinetics of cancer cell growth in
vitro. While the empty control vector (ECV) did not alter the growth rates of either PDAC
cell line, transduction with each of the three sgRNAs led to a significant decrease in overall
proliferation (Fig 3.1B), suggesting a phenotype specific to PTPMT1 depletion.
For all subsequent experiments, we pooled the three sgRNAs (sgPTPMT1) for
robust PTPMT1 ablation (Fig. 3.2 and Fig 3.3A). Reduced growth rates were confirmed
in both cell lines following transduction with the pooled PTPMT1 sgRNAs (Fig 3.3B).
Similar loss of growth following PTPMT1 ablation was observed in several other PDAC
cell lines (Fig 3.4A and 3.4B). Accompanying the impaired growth were morphological
changes, specifically a transition from epithelial-like to spindle cell shape, observed
through bright-field microscopy (Fig 3.5A). There were no substantial alterations in the
average cell size (Fig 3.5B).
To assess whether loss of PTPMT1 reduced the clonogenicity of cancer cells, we
performed colony formation assays (Fig 3.3C). Plating efficiency (the percentage of
monodispersed cells from initial seeding that formed colonies) was reduced by greater
than 50% in both cell lines (Fig 3.3D). Commensurate with cells exhibiting stunted growth
rates, the average size of each colony was also significantly smaller (Fig 3.3E). We then
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investigated if PTPMT1 ablation impairs growth of tumors in an orthotopic xenograft
mouse model. Four days after lentiviral transduction and puromycin selection, sgPTPMT1
and ECV S2-013 cells were injected into the pancreata of nude mice. Through ultrasound
imaging, we observed significantly reduced tumor volumes in the group of mice injected
with sgPTPMT1 cells (Fig 3.3F and 3.3G). Together, these results demonstrate that
PTPMT1 is important for cancer growth both in vitro and in vivo by sustaining clonogenicity
and cell proliferation.

Loss of PTPMT1 delays cell cycle progression without altering cell viability
A potential explanation for slower growth rates observed in sgPTPMT1 cells is that
cell death is occurring more frequently. To determine if the decreased growth rates were
due to increased apoptosis, we stained cells with propidium iodide and Annexin V. Only a
marginal difference in baseline apoptosis or cell death was detected between sgPTPMT1
and ECV cells (Fig 3.6A). Furthermore, PARP cleavage was assessed through western
blot at several time points following transduction and, likewise, no differences were
observed. (Fig 3.6B). This is in contrast to a previous study using a transient siRNAmediated knockdown of PTPMT1 that showed increased apoptosis in various cancer cell
lines [199]; nonetheless, our results are consistent with multiple studies using cells derived
from conditional PTPMT1 knockout mice, where PTPMT1 had no influence on cellular
viability [89, 200, 201].
Given that PTPMT1 ablation did not induce cell death, we tested whether the loss
of growth was due to decreased rates of cell division using a CFDA-SE labeling assay.
After a 24- and 48-hour culturing period, loss of PTPMT resulted in significantly increased
retention of CFSE fluorescence (Fig 3.7A and 3.7B), confirming that PTPMT1-ablated
cells underwent fewer cell divisions. Flow cytometric analysis of propidium iodide-stained
nuclei was then performed to investigate whether the decreased proliferation was
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associated with cell cycle perturbations. As compared to controls, sgPTPMT1 cells
displayed significantly delayed progression from G1, with a corresponding decrease in the
proportion of cells in S phase (Fig 3.7C).

Time-dependent decrease in growth rates correspond with depleted
cardiolipin levels
To test whether PTPMT1 has a direct role in cell proliferation, we quantified in vitro
growth rates at early and late time points following lentiviral transduction. While the growth
kinetics of ECV cells were identical at 4 and 10 dpi (days post infection), sgPTPMT1 cells
displayed significantly slower growth rates at 10 dpi (Fig 3.9A). This result, combined with
the finding that PTPMT1 protein levels were not detectable at any time points tested (Fig
3.10A), supported the hypothesis that the decrease in proliferation was due to the
cumulative loss of a catalytic product rather than PTPMT1 itself. Thus, we predicted that
the time-dependent decrease in growth rates was a reflection of the slow turnover and
gradual depletion of CL.
In order to quantify CL content, we extracted total lipids and utilized an enzymaticbased assay. The specificity of this assay is predicated on the presence of a glycerol head
group found only on phosphatidylglycerol and CL lipid species. Using bovine heart CL, we
established a standard curve showing a linear relationship between the concentration of
CL and fluorescence intensity (Fig 3.8A). To validate the specificity of this assay, an
interference study was performed with phosphatidylcholine and phosphatidylserine, which
are two of the most abundant lipids found in mammalian cells. Even at concentrations 10fold higher than CL, phosphatidylcholine and phosphatidylserine generated only a minor
fluorescence signal (Fig 3.8B). Using this assay, we quantified CL/PG in our samples at
multiple time points and observed a time-dependent decrease in PTPMT1-depleted cells
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(Fig 3.9B) that was consistent with the decrease in growth rates observed at 4 and 10 dpi.
To determine whether mitochondrial biomass influenced the CL/PG measurements, we
evaluated the expression of Tom20, a mitochondrial marker, by western blot and
quantified mitochondrial DNA copy number through qPCR analysis. No significant
decrease in Tom20 or mtDNA was observed in the sgPTPMT1 cells compared to the
controls at any of the time points tested (Fig 3.10A and 3.10B), suggesting that loss of
PTPMT1 altered CL levels but not mitochondrial biomass.

Ultrastructural features of mitochondria are disturbed by PTPMT1 ablation
As a major component of the IMM, CL has been linked to cristae organization [82].
To determine whether the loss of CL associated with PTPMT1 ablation affected
mitochondrial ultrastructure, ECV and sgPTPMT1 cells at 13 dpi were subjected to
transmission electron microscopy (TEM). Compared to the controls (Fig 3.11A), we
observed major structural alterations in the mitochondria of PTPMT1-ablated cells. In both
T3M4 and S2-013 cells, loss of PTPMT1 resulted in concentric, densely packed cristae,
resembling onion-like structures (Fig 3.11B).

PTPMT1 deficiency impairs mitochondrial respiration and metabolism
Given the morphological changes observed in the mitochondria of PTPMT1depleted cells, we subsequently investigated the effects on mitochondrial function. A
Seahorse Extracellular Flux assay revealed that PTPMT1 ablation and commensurate
reduction in CL resulted in decreased oxygen consumption rates (OCR) (Fig 3.12A). The
cellular bioenergetic parameters measured from this assay showed significantly reduced
basal and maximal respiration along with reduced respiration-coupled ATP production in
sgPTPMT1 cells, compared to controls (Fig 3.12C). Furthermore, sgPTPMT1 cells
displayed a decreased ratio of OCR to extracellular acidification rate (ECAR) (Fig 3.12C).
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ECAR is an indirect measurement of lactate production resulting from glycolysis. Thus, a
reduced OCR/ECAR ratio suggested that the sgPTPMT1 cells had shifted towards
glycolysis for supporting their metabolic demands. Interestingly, despite the glycolytic
compensation observed in PTPMT1-ablated cells, glycolytic reserve, which is the
difference in ECAR measurements following oligomycin treatment, was suppressed (Fig
3.12B). This suggested that the loss of PTPMT1 not only impaired mitochondrial
respiration, but also limited glycolytic capacity.
An intact mitochondrial membrane potential (m) is a key requirement for
oxidative phosphorylation (OXPHOS). To approximate m, we stained cells with
tetramethylrhodamine ethyl ester (TMRE), a positively charged dye that is sequestered in
the inner mitochondrial space due to the proton gradient. Carbonyl cyanide mchlorophenyl hydrazine (CCCP) is an uncoupler of the proton gradient and was used to
measure m -independent TMRE staining as background. In PTPMT1-deficient cells,
TMRE signal was significantly reduced (Fig 3.13A and 3.13B), reflecting mitochondria that
exhibit decreased or possibly absent m. Furthermore, we observed a gradual loss of
m following PTPMT1 ablation (Fig 3.13C) that mirrored the time-dependent decrease
in growth rates and CL content.
In addition to producing ATP via OXPHOS, a major function of mitochondria is to
generate metabolic intermediates required for cell growth. Thus, we conducted liquid
chromatography-coupled tandem mass spectrometry (LC-MS/MS)-based metabolomics
analyses to assess the metabolic changes that result from PTPMT ablation. PCA analysis
and hierarchical clustering revealed distinct metabolic profiles between sgPTPMT1 cells
and their controls (Fig 3.15A and 3.15B). Pathway analysis of significantly down-regulated
metabolites revealed that TCA and pyrimidine metabolism were the most impacted by the
loss of PTPMT1 (Fig 3.15C). Strikingly, we found that nearly all TCA metabolites were
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significantly decreased in both T3M4 and S2-013 upon PTPMT1 depletion (Fig 3.14).
Pyrimidine metabolites were also mostly reduced, including N-carbamoyl-L-aspartate,
which is the first committed product in pyrimidine biosynthesis (Fig 3.15D). Broadly, amino
acid levels were not altered in sgPTPMT1 cells, with the exception of aspartate and
asparagine, which were significantly decreased and increased respectively (Fig 3.15E).
Interestingly, previous studies have shown that supporting aspartate biosynthesis is a
major role of respiration in proliferating cells and that supplying aspartate supports growth
of respiration-deficient cells [202, 203]. However, in our studies, we did not observe a
rescue to the growth deficiency of sgPTPMT1 cells with aspartate supplementation (Fig
3.16).

Targeting PTPMT1 enhances sensitivity to glycolytic inhibition
While the loss of PTPMT1 resulted in mitochondrial dysfunction and growth
inhibition, minimal effects on cell viability were observed. This may have been due to
glycolytic compensation, which was sufficient for preventing cell death but inadequate for
maintaining cell division. To test whether PTPMT1-ablated cells were sensitized to
glycolytic inhibition, we treated cells with the glucose analog, 2-DG. Following 24-hour
incubation with different concentrations of the glycolytic inhibitor, we observed significantly
reduced cell viability in PTPMT1-depleted cells, compared to controls (Fig 3.17A).
We also investigated pharmacological inhibition of PTPMT1, to validate the genetic
ablation studies. Alexidine dihydrochloride is a selective inhibitor of PTPMT1 with an IC50
of around 1uM in-vitro [191]. Pretreatment with a sublethal dose of 4M alexidine
significantly potentiated the effect of 2-DG on both T3M4 (Fig 3.17B) and S2-013 cells
(Fig 3.17C). The combination of alexidine and 2-DG at all concentrations tested yielded a
coefficient of drug interaction (CDI) far less than 1, indicating a highly synergistic effect
(Fig 3.17E and 3.17F). Interestingly, when this combination was tested against a non-
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transformed pancreatic epithelial cell line, HPNE, we did not observe any further loss in
viability compared to 2-DG alone (Fig 3.17D). The CDI values for HPNE at all
concentrations tested were close to 1, suggesting only an additive effect (Fig 3.17G).
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Discussion
Over the last several decades, improvements in survival for PDAC have been
marginal and overwhelmingly inadequate. While targeting oncogene-driven signaling
pathways represents a clinically validated approach for several cancer types, KRAS
mutations, reported in up to 90 percent of PDAC patients, currently stands undruggable
[17]. The only targeted therapy approved for PDAC is the EGFR inhibitor erlotinib, which
extends life by less than a month when used in combination with gemcitabine [18]. Even
the recent breakthroughs of cancer immunotherapy, such as PD-1 and CTLA-4 checkpoint
blockade, have not translated to success in the clinical setting for PDAC [19]. Thus, there
is an urgent need to identify novel therapeutic strategies that can improve patient
outcomes. Here, we demonstrate that targeting CL biosynthesis through inhibition of
PTPMT1 can suppress tumor growth and render pancreatic cancer cells vulnerable to
metabolic stress.
While we recognize that CL is also critical for mitochondrial function in normal cells,
the rationale for targeting this pathway is that cancer cells upregulate CL biosynthesis as
part of a lipogenic program to meet the demands of proliferation [204]. Several studies
have shown that activation of oncogenes, including KRAS [153], c-myc [155], and mTORC
[158] lead to increased CL levels. Furthermore, CL is highly stable with a half-life that is
several-fold longer than that of other phospholipids [96]. Isotope labeling studies in
Drosophila showed no measurable turnover in CL over a span of at least 9 days [97]. This
stability is due to its interaction with protein complexes, which promotes mutual protection
from degradation [90]. Thus, CL biosynthesis occurs at a minimal rate in most
differentiated cells, providing a potential therapeutic window. To further limit toxicity, the
combination of CL biosynthesis inhibition with newly developing CL-protective agents
[205] may represent a viable therapeutic option in the future.
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In our study, we showed that PTPMT1 is an effective target for inhibiting CL
biosynthesis. Currently, the only known function of PTPMT1 is to generate the CL
precursor PG. Conventional knockout of PTPMT1 is embryonically lethal [89, 200].
However, consistent with our observations, loss of PTPMT1 did not directly induce cell
death, rather PTPMT1-/- embryos became non-viable only after implantation. The reason
for embryonic lethality is not completely understood, but it is hypothesized that PTPMT1
is necessary for rapid mitochondrial biogenesis that occurs in embryos post-implantation
[89]. In addition, conditional PTPMT1 knockouts in hematopoietic stem cells blocked
differentiation, while a restricted myeloid, T lymphoid, or B lymphoid lineagespecific PTPMT1 knockout showed no abnormalities [206]. The implication is that
targeting PTPMT1 activity may be compatible with combined strategies that include
cancer immunotherapy.
Following PTPMT1 ablation, we observed altered mitochondrial ultrastructure,
namely a concentric, onion-like appearance to the inner membranes. Interestingly, these
structures were strikingly similar to the mitochondria of cells lacking mitofilin [207], a chief
component of the MICOS complex (mitochondrial contact site and cristae organizing
system), suggesting that CL may be required for MICOS activity. Furthermore, we showed
that these morphological defects were associated with impaired respiratory function and
TCA metabolism. Previous studies have demonstrated that growth deficiency due to
defective OXPHOS can be rescued with aspartate supplementation [202, 203]. In fact, the
scavenging of nutrients, like aspartate, from the tumor microenvironment is a potential
source of resistance to OXPHOS inhibitors in cancer therapy [208]. That PTPMT1depleted cells could not be rescued with exogenous aspartate suggests that the
mitochondrial impairment caused by CL deficiency extends beyond respiratory defects.
Thus, targeting CL biosynthesis may have an advantage over the use of electron transport
chain inhibitors, such as metformin, which failed to improve outcomes in pancreatic cancer
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patients when added to standard therapy [209].
We also demonstrated that loss of PTPMT1 activity decreased OCR/ECAR ratio,
indicating an increased dependence on glycolytic metabolism. Accordingly, both genetic
and pharmacological inhibition of PTPMT1 using alexidine dihydrochloride potentiated the
effects of a glycolytic inhibitor, 2-DG, in pancreatic cancer cells. Interestingly, alexidine
and 2-DG did not exhibit synergy in a normal pancreatic epithelial cell line. Alexidine is a
positively charged compound that localizes to the mitochondria for the same reason that
TMRE can be used to measure m. Because cancer cells tend to have hyperpolarized
mitochondria [210], alexidine may accumulate to a higher degree in cancer cells relative
to normal cells, which would explain the difference in response at the concentrations
tested. Prior to being recognized as a PTPMT1 inhibitor, alexidine was similarly shown to
preferentially reduce cell viability in human hypopharyngeal squamous cancer over
untransformed cells [211]. While alexidine inhibits PTPMT1 activity, it also non-specifically
disrupts cell membrane integrity at higher concentrations [191] and thus is not a candidate
for clinical trials. Rather, it serves as a proof-of-concept for future development of specific
PTPMT1 inhibitors. In summary, our results demonstrate that targeting cardiolipin
biosynthesis through PTPMT1 is a potential therapeutic strategy to impair mitochondrial
metabolism required for pancreatic cancer growth.

85

Figure 3.1 CRISPR/Cas9-mediated PTPMT1 ablation
(A) Immunoblot analysis from whole cell lysates for PTPMT1 expression following
transduction with three different sgRNAs, using β-actin as loading control. (B) In vitro
growth curves were determined for cells transduced with ECV and the individual sgRNAs
through methylene blue-based assay.
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Figure 3.2 PTPMT1 expression is localized to the mitochondria
Representative confocal images of ECV and sgPTPMT1 cells, stained with PTPMT1 and
Tom20. The individual channels as well as their overlay (including nuclear staining with
DAPI) are shown. Scale bar represents 20m.
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Figure 3.2
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Figure 3.3 PDAC cells depend on PTPMT1 for growth in vitro and in vivo.
(A) Whole cell lysates were immunoblotted for PTPMT1 expression following transduction
with the pooled sgRNAs, using β-actin as loading control. (B) In vitro growth curves were
determined for cells transduced with ECV and the pooled sgRNAs through methylene
blue-based assay. (C) Colonies were grown for 10 to 20 days, fixed with
paraformaldehyde solution and stained with crystal violet (n=3). The number (D) and size
(E) of colonies were analyzed through Fiji (ImageJ) software. Plating efficiency was
determined by the percentage of cells from initial seeding that resulted in colony formation.
(F) S2-013 ECV and sgPTPMT1 cells were injected orthotopically into the pancreata of
nude mice and tumor volumes were measured weekly by ultrasound (n=5 per group). (G)
Representative ultrasound images of tumors 18 days post-injection. Dashed lines indicate
the margins of the tumor. Data are shown as mean  SD. *p < 0.05; **p < 0.01; ***p <
0.001.
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Figure 3.4 PTPMT1 ablation impairs growth of multiple PDAC cell lines
(A) Whole cell lysates were immunoblotted for PTPMT1 using β-actin as loading control.
(B) In vitro growth curves were determined by a methylene blue-based assay.
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Figure 3.5 Altered cell morphology following PTPMT ablation
(A) Representative images taken from a light microscope. (B) Cell diameters were
assessed by Countess II (Invitrogen) (n=4).

94

Figure 3.5

A

B

95

Figure 3.6 Loss of PTPMT1 does not induce cell death
(A) Ten days after lentiviral transduction with ECV or sgPTPMT1, FACS analysis of
Annexin V-FITC / propidium iodide-stained cells was performed to measure the induction
of apoptosis and cell death. (B) Whole cell lysates from the indicated time points were
immunoblotted for PTPMT1 and PARP cleavage, using β-actin as loading control.
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Figure 3.7 Delayed cell cycle progression is caused by PTPMT deficiency
(A) Representative overlay histogram shows CFDA-SE stained cells as analyzed by flow
cytometry. Dashed line serves as a point of reference. (B) Percent retention in median
fluorescence intensity (MFI) for CFDA-SE stained cells was quantified after a 24-hour
incubation (n=3). (C) Cycle distribution was determined by flow cytometric analysis
following fixation with ethanol and propidium iodide staining (n=3). Data are shown as
mean  SD. *p < 0.05; **p < 0.01
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Figure 3.8 Enzymatic quantification of cardiolipin
(A) An enzymatic-based cardiolipin quantification assay was used to generate a standard
curve illustrating a linear relationship between the cardiolipin concentration and relative
fluorescence. (B) Specificity of the assay was tested using phosphatidylcholine (PC) and
phosphatidylserine (PS).
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Figure 3.9 Decreased growth rates are associated with cardiolipin levels
(A) In vitro growth curves were determined at 4 and 10 dpi for both ECV and sgPTPMT1
cells using a methylene blue-based assay. (B) Enzymatic quantification of CL/PG was
performed on total lipids extracted from samples at the given time points (n=2). Data are
shown as mean  SD. *p < 0.05; **p < 0.01
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Figure 3.9
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Figure 3.10 Cardiolipin depletion is not due to reduced mitochondrial biomass
(A) Whole cell lysates from the indicated time points were immunoblotted for PTPMT1 and
Tom20, using β-actin as loading control. (B) Total DNA were extracted at the indicated
time points and mitochondrial DNA copy number was quantified through qPCR using
genomic DNA as reference.
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Figure 3.11 Loss of PTPMT1 alters mitochondrial ultrastructure
Representative transmission electron microscope (TEM) images are shown for ECV (A)
and sgPTPMT1 (B) transduced cells at 13 dpi. Black arrows indicate the concentric,
“onion-like,” cristae structure. White arrows indicate mitochondria devoid of any visible
cristae. Bar, 500 nm.
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Figure 3.12 PTPMT1 supports mitochondrial respiration
(A) Oxygen consumption rates (OCR) and (B) extracellular acidification rates (ECAR)
were measured at baseline conditions and after sequential injections of oligomycin, FCCP,
and rotenone using the Seahorse XFe96 Analyzer (n=3). (C) Parameters of mitochondrial
respiration was calculated from the OCR and ECAR measurements. The OCR/ECAR ratio
was derived from the baseline OCR and ECAR measurements. Data are shown as mean
 SD. *p < 0.05; **p < 0.01; ***p < 0.001.
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Figure 3.13 PTPMT1 deficiency impairs mitochondrial membrane potential
(A) Representative overlay histogram depicts relative mitochondrial membrane potential
as indicated by the intensity of TMRE staining. CCCP is an uncoupler of the proton
gradient and shows the background TMRE staining that is independent of the
mitochondrial membrane potential. (B) The relative TMRE median fluorescence intensity
(MFI) of sgPTPMT1 compared to ECV controls was calculated (n=3). (C) Representative
overlay histograms depict change in mitochondrial membrane potential, as measured by
TMRE, over several time points following sgPTPMT1 or ECV transduction. Data are
shown as mean  SD. *p < 0.05; ***p < 0.001.
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Figure 3.14 TCA anaplerosis requires PTPMT1
Polar metabolites were extracted 10 days following transduction with ECV or sgPTPMT1.
Relative levels of TCA cycle intermediates were measured by LC-MS/MS (n=4). AcCoA,
acetyl-CoA; Cit, citrate; Aco, aconitase; Iso, isocitrate; -KG, alpha-ketoglutarate;
SucCoa, succinyl-CoA; Suc, succinate; Fum, fumarate; Mal, malate. Data are shown as
men  SD. *p < 0.05; **p < 0.01; ***p < 0.001.
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Figure 3.14
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Figure 3.15 PTPMT1 ablation alters PDAC metabolism
(A) Principal component analysis (PCA). Explained variances of selected PCs are shown
in brackets. (B) Hierarchical clustering result of the top 75 differential metabolites shown
as heatmap (distance measure using Euclidean, and clustering algorithm using Ward). (C)
Metabolic pathway impact analysis of significantly downregulated metabolites by
MetaboAnalyst 4.0 in sgPTPMT1 cells compared with ECV cells. Relative level of
pyrimidine metabolites (D) and amino acids (E) were measured by LC-MS/MS (n=4). Data
are shown as mean  SD. *p < 0.05; **p < 0.01; ***p < 0.001.
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Figure 3.16 Aspartate supplementation does not rescue PTPMT deficiency
Relative in vitro growth was assessed using a methylene blue-based assay. Cells were
cultured in base medium or media supplemented with 20mM L-Aspartic Acid (SigmaAldrich).
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Figure 3.16
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Figure 3.17 Targeting PTPMT1 activity potentiates the efficacy of glycolytic
inhibition
(A) Cell viability was assessed on sgPTPMT1 and ECV cells treated with the glycolytic
inhibitor, 2-DG. The percent of viable cells were measured by XTT assay at 24 hours
relative to untreated controls (n=2). Parental T3M4 (B), S2-013 (C), and HPNE (D) cells
were pretreated with DMSO or 4M of the PTPMT1 inhibitor, alexidine dihydrochloride,
for 24 hours and then treated with 2-DG. Cell viability was measured by XTT after 24 hours
relative to DMSO-treated controls (n=2). The coefficient of drug interaction (CDI) for
alexidine and 2-DG at the concentrations tested were calculated for T3M4 (E), S2-013 (F),
and HPNE (G) cells. CDI values <1, = 1 or >1 indicates that the drugs are synergistic,
additive or antagonistic, respectively. Data are shown as mean  SD. *p < 0.05; **p < 0.01;
***p < 0.001.
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Table 3.1 Primary antibodies and dilutions
Antibody

Vendor

Clone

Cat. #

Dilution

PTPMT1

Santa Cruz

B-3

sc-390901

1:1000

Tom20

CST

D8T4N

42406

1:1000

PARP

CST

Polyclonal

9542

1:1000

-actin

Sigma-Aldrich

AC-15

A1978

1:20000

Table 3.2 RT-PCR primers
Genome

Target
Gene

Amplicon
(bp)

Tm

F Primer 5’-3’

R Primer 3’-5’

Mitochondrial

tRNALeu

107

62

CACCCAAGAACAGGGTTTGT

TGGCCATGGGTATGTTGTTA

Nuclear

B2Microgl
obulin

86

62

TGCTGTCTCCATGTTTGATGTATCT

TCTCTGCTCCCCACCTCTAAGT
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Chapter IV: Discussion and Future Directions
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Overview
Mitochondria are complex organelles that confer on cancer cells the metabolic
flexibility to survive and grow in harsh tumor microenvironments. Accordingly,
mitochondrial metabolism represents a key vulnerability waiting to be exploited for
therapeutic purposes. This is particularly relevant for pancreatic cancer due to the limited
treatment options available and the fact that PDAC tumor microenvironments are
frequently characterized as desmoplastic and nutrient poor [183]. Identifying and
understanding the metabolic adaptations that drive tumor progression can unveil
exploitable targets for cancer therapy.
In the first half of this dissertation, we highlighted the importance of mitochondriadependent metabolic flexibility of PDAC cells upon exposure to acidic conditions. An acidic
tumor microenvironment is a common feature of many solid tumors and exerts a profound
influence on cancer biology [212]. Similar to previous findings, we demonstrated that low
extracellular pH induces EMT and enhances cancer cell invasiveness [165, 213, 214].
Unexpectedly, we observed that acidification below a certain threshold impaired cancer
invasion despite elevated EMT markers. While we suspect this may have been due to
compromised motility stemming from bioenergetic deficiency, it would be of interest to
further characterize these observations. A potential implication from our initial findings
(refer to Fig 2.10) is that ATP present in the tumor microenvironment milieu, which has
been documented to reach hundreds of micromolar in concentration [215], may rescue
the invasive properties that are suppressed in highly acidic conditions.
Though EMT is regularly associated with an increased glycolytic phenotype [173,
216, 217], we found that acidity-driven EMT was coupled to decreased glucose uptake
and utilization. This corresponded with increased resistance to glucose starvation. These
are significant findings suggesting that metabolic reprogramming in cancer is not
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completely “hard-wired” and may partially explain why efforts to target the Warburg effect
have only been met with limited clinical success. Shifting metabolism away from aerobic
glycolysis is likely a homeostatic response to prevent further acidification of the tumor
microenvironment. Our observation that proliferation and invasion are impaired below a
certain pH threshold lends credence to the rationale for tumors to limit the acidity of their
microenvironment.
Subsequently, we determined that cancer cells shifted their dependence from
glycolysis to mitochondrial metabolism. This was confirmed using respiration-deficient
cells, which did not exhibit enhanced invasion nor resistance to glucose starvation under
acidic conditions. Furthermore, we found that lipid uptake and FAO were increased,
suggesting that fatty acids may have been the primary choice of fuel for oxidative
phosphorylation. While the role of FAO in cancer remains poorly understood, others have
reported it to be a crucial survival mechanism in cancers undergoing stress [42]. Moreover,
we demonstrated that inhibiting FAO with etomoxir suppressed low pH-induced invasion.
Together, our findings raise additional questions about the role of fatty acids and FAO in
cancer. Future studies should address how fatty acids are being taken up and whether
there is a preference for certain types. This may help uncover additional pathways or
biological processes that can serve as therapeutic targets. It would also be of interest to
investigate whether the fatty acids are primarily being oxidized to generate ATP or if they
are being utilized for other purposes as well, such as the direct incorporation into
phospholipids. The PDAC cells cultured at pH 6.8 exhibit increased FAO while still
maintaining proliferation. Thus, assuming that most of the exogenous fatty acids are being
utilized for bioenergetic needs, it would be interesting to investigate the status of fatty acid
synthesis and whether it occurs concurrently with FAO under acid conditions.
In the second half of this dissertation, we proposed that modulating cardiolipin
metabolism is a potential therapeutic strategy for targeting mitochondrial function in
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cancer. Several oncogenic signaling pathways, including those involving K-Ras, c-Myc,
and mTOR, have been shown to increase cardiolipin biosynthesis as part of a lipogenic
reprogramming [153, 155, 158]. In order to support the biosynthetic and bioenergetic
demands of tumor growth, cancer cells upregulate mitochondrial biogenesis [40]. Given
that cardiolipin makes up a large fraction of the inner mitochondrial membrane and is
indispensable for proper mitochondrial function [185], we hypothesized that cancers may
be vulnerable to the inhibition of cardiolipin biosynthesis. The need for newly synthesized
cardiolipin is likely to be further amplified by the elevated levels of ROS observed in cancer
cells, which leads to increased degradation of cardiolipin [218]. Together with the fact that
there is very little turnover of cardiolipin in most normal tissue makes cardiolipin
metabolism an appealing target for cancer therapy [96, 97].
To investigate the effects of disrupting cardiolipin biosynthesis in cancer, we
undertook a loss-of-function approach by ablating PTPMT1 through lentivirus-mediated
delivery of CRISPR/Cas9. PTPMT1 is a PTEN-like phosphatase involved in the generation
of phosphatidylglycerol, a cardiolipin precursor [89]. We found that PTPMT1 supports the
growth of pancreatic cancer cells both in vitro and in an orthotopic tumor model. Upon
PTPMT1 ablation, we observed a time-dependent decrease in proliferation commensurate
with reduced cardiolipin levels. This resulted in altered mitochondrial ultrastructure,
impaired oxidative phosphorylation, and depleted TCA cycle intermediates. Future studies
utilizing rescue experiments to identify the mechanisms by which loss of cardiolipin impairs
proliferation would provide meaningful biological insight. Remarkably, the changes
induced by cardiolipin depletion did not induce cell death as determined by annexin V
staining and PARP cleavage. Likewise, aside from the mitochondrial ultrastructure, the
TEM images showed intact cells with no other observable differences between the
controls and PTPMT-deficient cells. We suspect that that cancer cells were able to survive
due to aerobic glycolysis, which can compensate to maintain cellular ATP levels under
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OXPHOS impairment. Indeed, PTPMT1-deficient cells exhibited increased basal levels of
glycolysis. Moreover, pharmacological and genetic inhibition of PTPMT1 activity resulted
in increased sensitivity to glycolytic inhibition. Thus, targeting cardiolipin biosynthesis may
be an effective strategy for limiting the mitochondria-dependent metabolic flexibility
necessary for cancer growth. Nevertheless, more extensive studies investigating the
impact of PTPMT inhibition in normal tissue are still required.
Overall, the results from this dissertation underscore the importance of
mitochondrial metabolism in malignant progression and offer novel insight regarding
potential therapeutic avenues for pancreatic cancer treatment. Furthermore, in addition to
the questions and studies that were already proposed in this discussion, our findings also
set the framework for future studies that will be discussed in the following sections.

Investigate the role of TGM2 in mediating EMT and metabolic
changes induced by acidic conditions
While we have demonstrated that an acidic extracellular environment can induce
EMT and promote cancer invasion, the molecular mechanisms that drive those changes
are unknown. Previously, we had generated a preliminary RNA-seq analysis of T3M4 cells
cultured under low extracellular pH conditions. The lists of significantly upregulated and
downregulated genes are shown in Tables 4.1a and 4.1b, respectively. One of the
differentially expressed genes that caught our attention was tissue glutaminase 2 (TGM2),
a multifunctional enzyme that can crosslink glutamine and lysine residues as well as
perform other catalytic reactions, such as deamidation and GTP-hydrolysis. TGM2
induction at the protein level by low extracellular pH was further validated by immunoblot
analysis (Fig 4.1A) Elevated levels of TGM2 have been reported in most cancer types,
including pancreatic cancer [219], breast cancer [220], lung cancer [221], renal cell
carcinoma [222], ovarian carcinoma [223], and melanoma [224]. Furthermore, TGM2
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expression was found to be prognostic for metastatic progression, chemotherapy
resistance, and reduced overall survival [220, 225]. Utilizing TCGA data, we confirmed the
association with reduced survival in pancreatic cancer (Fig 4.1B). Several studies have
reported that TGM2 induces EMT through mechanisms that require further investigation
[226-228]. Given the established connection to EMT, we hypothesize that TGM2 may have
a role in mediating the invasive and metabolic phenotypes that are induced by acidic
conditions, something that has never been explored previously.
TGM2 has both enzymatic and signaling functions that are considered to be
mutually exclusive due to conformational differences. When bound to Ca2+, TGM2 posttranslationally modifies glutaminyl sidechains by transamidation, deamidation, or
esterification [229]. TGM2-catalyzed transamidation between glutamine and lysine
residues can form crosslinks on a wide spectrum of proteins and drastically alter stability
and/or function [229]. However, when TGM2 binds GTP, the calcium binding site becomes
inaccessible and TGM2 functions as a G protein that can trigger various signaling
programs [230]. While the signaling function is considered the mechanism by which TGM2
induces EMT [231], it’s possible that the enzymatic activity of TGM2 may also be involved.
This is because extracellular acidosis has been shown to increase intracellular Ca2+
through activation of acid-sensing ion channels (ASIC) [232]. Furthermore, ASIC1 and
ASIC3 have been reported to contribute to acidity-induced EMT of pancreatic cancer cells
[213]. Thus, we hypothesize that the calcium-dependent enzymatic activity of TGM2 may
have an important role in mediating the invasive and/or metabolic phenotypic changes
observed in acidic conditions. In preliminary studies, we found that ZDON, a peptidebased TGM2 inhibitor, was able to suppress invasion induced by low extracellular pH (Fig
4.1C). While ZDON is known to block the crosslinking activity of TGM2, it’s unknown
whether ZDON also inhibits the GTPase activity. Thus, further investigations using
CRISPR-mediated gene editing and Ca2+-chelating agents are currently underway.
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Assess FAO and TGM2 inhibitors in mouse models of metastasis
While we have demonstrated that etomoxir and ZDON can suppress invasion
induced by low extracellular pH in vitro, further studies are required to evaluate their
potential for use as adjunct therapy in the clinical setting. Thus, we plan to investigate the
ability of these inhibitors to prevent metastasis and promote survival in two different mouse
models of metastasis.

Experimental metastasis model
Previous studies have demonstrated that tail vein injection of melanoma cell lines
exposed to low extracellular pH results in greater number of pulmonary metastases [171].
We intend to establish a similar model using GFP-labeled PDAC cell lines. After validation
studies to confirm that PDAC cells cultured in acidic conditions generate more tumors in
the lungs, we would investigate whether or not our inhibitors can modulate the number of
tumors formed. Considering the results from our in vitro studies, we hypothesize that
pretreatment of mice with etomoxir or ZDON will suppress acidity-induced metastases to
the lungs. As an alternative to tail vein injection, intrasplenic injection of pancreatic tumor
cells to simulate the development of liver metastases has been previously described [233].
Given that the liver is by far the most commonly observed site of metastases in PDAC
patients [234], this experimental model may be more biologically relevant and should also
be considered for the evaluation of FAO and TGM2 inhibitors.

KPC mouse model
While

the

experimental

metastasis

models

provide

convenience

and

reproducibility, a major limitation is that early steps of the metastatic cascade are not
recapitulated, including invasion through the basement membrane and hematogenous or

127

lymphatic intravasation. Thus, we intend to complement the experimental metastasis
studies with the KPC mouse model, which spontaneously give rise to pancreatic tumors
capable of completing the entire metastatic process [10]. Importantly, recent reports
utilizing pH-sensitive peptide probes have confirmed the development of an acidic
intratumoral environment in KPC mice [235]. For these studies, FAO and TGM2 inhibitors
will be given in conjunction with gemcitabine to determine their efficacy for preventing
metastatic spread and increasing overall survival.

Develop a conditional PTPMT1 knockout KPC mouse model
Although we demonstrated that PTPMT1 ablation leads to reduced tumor growth
rates following orthotopic injections, the conclusions that can be made from our results
are limited due to the nature of our loss-of-function model. Previously, we had observed
that after approximately 30 days post PTPMT1 deletion by lentivirus-mediated CRIPSR
gene editing, the knockout cell population were counter-selected (Fig. 4.2A) and culture
growth rates returned to normal (Fig 4.2B and 4.2C). This stems from the fact that
CRISPR editing was performed on bulk treated cells that were selected for puromycin
resistance, resulting in a mixed population where a small percentage of the cells retain
intact PTPMT1 expression, likely due to an in-frame deletion in at least one of the alleles.
Furthermore, we have attempted single cell cloning experiments many times that failed to
produce any clones that grow progressively. Thus, while we can make the assertion that
PTPMT1 is necessary for growth in vitro, the same cannot be said in vivo given that the
tumors were derived from a mixed clonal population.
Therefore, it would be of interest to cross PTPMT1 floxed mice, which are available
in cryopreservation at The Jackson Laboratory, into the KPC (LSL-KrasG12D/+; LSLp53R172H/+, Pdx-1-Cre) and KC (LSL-KrasG12D/+; Pdx-1-Cre) mouse models of pancreatic
cancer. These studies would address whether PTPMT1 expression is required in the
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formation and/or progression of pancreatic cancer. While we would hypothesize that
cardiolipin biosynthesis is necessary for tumorigenesis, it is possible that there are
PTPMT1-independent mechanisms for generating cardiolipin – in which case, PTPMT1knockout tumors may develop. Studying the compensatory means that allow for these
tumors to grow will not only help us to predict and neutralize potential mechanisms of
resistance associated with PTPMT1-targeted therapy but will also extend our fundamental
understanding of cardiolipin biosynthesis.

Conclusion
With the discovery of oncogenes and tumor suppressors, cancer has become
widely considered a genetic disease. However, detailed examination into the function of
most oncogenes suggest that cancer is still fundamentally a metabolic disease. While
there may be a seemingly infinite number of mutations that can drive cancer development,
they all influence common metabolic pathways that allow for tumors to meet the
bioenergetic and biosynthetic requirements of unconstrained growth. Thus, cancer
metabolism is a fertile area of research that can lead to therapeutic opportunities,
especially for cancers like PDAC in which targeted therapies are not currently effective.
Specifically, mitochondrial metabolism represents a promising target to limit the metabolic
flexibility necessary for cancer growth. The tumor microenvironment presents several
challenges for cancer cells to meet their basic metabolic demands, such as hypoxia,
acidosis, and nutrient deprivation. Under these conditions, cancers require the ability to
utilize various source of nutrients that are catabolized through mitochondrial metabolism.
The findings presented in this dissertation highlight the dependency of cancers on
mitochondria-dependent metabolic flexibility and contribute to the overall understanding
of how mitochondria support malignant properties. Furthermore, our work also provides
novel insight into potential therapeutic strategies for targeting cancer metabolism.
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Figure 4.1 TGM2 mediates invasive phenotype induced by acidic conditions
(A) Kaplan-Meier survival curve from TCGA data analysis for TGM2 expression in
pancreatic cancer. P-value for significance of difference between high and low expression
was calculated using the log-rank test. (B) Immunoblot analysis for TGM2 expression from
whole cell lysates following 24-hour incubation at the indicated pHe conditions (7.4, 6.8, or
6.4), with β-actin as loading control. (C) Representative images from Matrigel invasion
assays. Suspension of T3M4 cells in pH 7.4 or pH 6.8 media were added into the inserts
and incubated with and without 100M ZDON for 22 hours. Bar, 400M.
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Figure 4.1
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Figure 4.2 Counter-selection of PTPMT1 expressing cells
(A) Immunoblot analysis for PTPMT1 expression from whole cell lysates following 10- and
30-days post infection with lentiCRISPR constructs, with β-actin as loading control. ECV,
empty control vector; dpi, days post infection. (B) In vitro growth was assessed using a
methylene blue-based assay 10 and 30 dpi. Data points are relative to the growth of ECV
cells and are shown as mean  SD. *p < 0.05.
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Table 4.1a List of upregulated genes (p<0.05 and at least 3-fold induction) under low
extracellular pH.
Gene Name

Description

SUSD3
SAMD11

sushi_domain_containing_3
sterile_alpha_motif_domain_containing_11

PTGDS
DRD4

prostaglandin_D2_synthase_21kDa_(brain)
dopamine_receptor_D4

FGF19
MEIS3

fibroblast_growth_factor_19
Meis_homeobox_3

SCARF2
BAIAP3
ADAMTSL4
NKAIN1P1

scavenger_receptor_class_F_member_2
BAI1-associated_protein_3
ADAMTS-like_4
Na+/K+_transporting_ATPase_interacting_1_pseudogene_1

KNDC1
TMEM59L

kinase_non-catalytic_C-lobe_domain_(KIND)_containing_1
transmembrane_protein_59-like

SPRR2A
TXNIP
RPS12P26
SYNGR3
ALDH3B1
SPERT
TMEM88B
UNC5A
PDZK1IP1
ARRDC4
IL1A
C11orf91
TMEM8B
SERPINB3
CILP2
COX6B2
MEGF6
H2AFB1
PCBP3
RP11-166B2.1
PCED1B
COX5BP6
NGFR

small_proline-rich_protein_2A
thioredoxin_interacting_protein
ribosomal_protein_S12_pseudogene_26
synaptogyrin_3
aldehyde_dehydrogenase_3_family_member_B1
spermatid_associated
transmembrane_protein_88B
unc-5_homolog_A_(C._elegans)
PDZK1_interacting_protein_1
arrestin_domain_containing_4
interleukin_1_alpha
chromosome_11_open_reading_frame_91
transmembrane_protein_8B
serpin_peptidase_inhibitor_clade_B_(ovalbumin)_member_3
cartilage_intermediate_layer_protein_2
cytochrome_c_oxidase_subunit_VIb_polypeptide_2_(testis)
multiple_EGF-like-domains_6
H2A_histone_family_member_B1
poly(rC)_binding_protein_3
NPIP-like_protein_LOC729978_
PC-esterase_domain_containing_1B
cytochrome_c_oxidase_subunit_Vb_pseudogene_6
nerve_growth_factor_receptor
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NHLRC4
CITED4
CRIP2
BCAN
ADAM19
PDGFB
C9orf172
SLC22A18
NFE2
FBXL16

NHL_repeat_containing_4
Cbp/p300-interacting_transactivator_with_Glu/Asprich_carboxy-terminal_domain_4
cysteine-rich_protein_2
brevican
ADAM_metallopeptidase_domain_19
platelet-derived_growth_factor_beta_polypeptide
chromosome_9_open_reading_frame_172
solute_carrier_family_22_member_18
nuclear_factor_(erythroid-derived_2)_45kDa
F-box_and_leucine-rich_repeat_protein_16

PROSER2
NTSR1

proline_and_serine-rich_protein_2
neurotensin_receptor_1_(high_affinity)

THBD
IL1B
MLXIPL
LEMD1
LMF1
SHISA3
FAM167A
GPSM1

thrombomodulin
interleukin_1_beta
MLX_interacting_protein-like
LEM_domain_containing_1
lipase_maturation_factor_1
shisa_homolog_3_(Xenopus_laevis)
family_with_sequence_similarity_167_member_A
G-protein_signaling_modulator_1

OSCAR
PADI1
BHLHA15
LPPR3
MFNG
MUC2
CDK18
DUSP8
RHBDF2

osteoclast_associated_immunoglobulin-like_receptor
peptidyl_arginine_deiminase_type_I
basic_helix-loop-helix_family_member_a15
hsa-mir-3187
MFNG_O-fucosylpeptide_3-beta-Nacetylglucosaminyltransferase
mucin_2_oligomeric_mucus/gel-forming
cyclin-dependent_kinase_18
dual_specificity_phosphatase_8
rhomboid_5_homolog_2_(Drosophila)

APCDD1L
MICALCL

adenomatosis_polyposis_coli_down-regulated_1-like
MICAL_C-terminal_like

RPL13P12
ARVCF

ribosomal_protein_L13_pseudogene_12
armadillo_repeat_gene_deleted_in_velocardiofacial_syndrome

P2RY6
EXD3
BBC3
TMEM240
PLEKHN1

pyrimidinergic_receptor_P2Y_G-protein_coupled_6
exonuclease_3'-5'_domain_containing_3
BCL2_binding_component_3
transmembrane_protein_240
pleckstrin_homology_domain_containing_family_N_member_1
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ODF3B
CHRNA4
KIF21B
SOCS2
JPH2
LHX5
SEMA3B
PODNL1
EFS
SOCS3

outer_dense_fiber_of_sperm_tails_3B
cholinergic_receptor_nicotinic_alpha_4_(neuronal)
kinesin_family_member_21B
suppressor_of_cytokine_signaling_2
junctophilin_2
LIM_homeobox_5
sema_domain_immunoglobulin_domain_(Ig)_short_basic_doma
in_secreted_(semaphorin)_3B
podocan-like_1
embryonal_Fyn-associated_substrate
suppressor_of_cytokine_signaling_3

DUSP8P5
FAM83E

dual_specificity_phosphatase_8_pseudogene_5
family_with_sequence_similarity_83_member_E

FAM131C
TNXB
IFITM2
FZD7

family_with_sequence_similarity_131_member_C
tenascin_XB
interferon_induced_transmembrane_protein_2
frizzled_family_receptor_7
transglutaminase_2_(C_polypeptide_protein-glutamine-gammaglutamyltransferase)
kelch_repeat_and_BTB_(POZ)_domain_containing_11
tyrosine_kinase_non-receptor_2

TGM2
KBTBD11
TNK2
C19orf26
KISS1R
MYCL1
RCN3
LMTK3
GJC2
LRRC73
WBSCR27
SAA1
FIBCD1
DMBX1
EXOC3L2
PLAT
ADM2
EPB49
SLC15A3
APC2
ULK2

chromosome_19_open_reading_frame_26
KISS1_receptor
vmyc_myelocytomatosis_viral_oncogene_homolog_1_lung_carc
inomaderived_(avian)
reticulocalbin_3_EF-hand_calcium_binding_domain
lemur_tyrosine_kinase_3
gap_junction_protein_gamma_2_47kDa
leucine_rich_repeat_containing_73
Williams_Beuren_syndrome_chromosome_region_27
serum_amyloid_A1
fibrinogen_C_domain_containing_1
diencephalon/mesencephalon_homeobox_1
exocyst_complex_component_3-like_2
plasminogen_activator_tissue
adrenomedullin_2
erythrocyte_membrane_protein_band_4.9_(dematin)
solute_carrier_family_15_member_3
adenomatosis_polyposis_coli_2
unc-51-like_kinase_2_(C._elegans)
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BTBD11
SERPINE1
TTLL1
PADI2
ADAM8
TAS1R3

BTB_(POZ)_domain_containing_11
serpin_peptidase_inhibitor_clade_E_(nexin_plasminogen_activa
tor_inhibitor_type_1)_member_1
tubulin_tyrosine_ligase-like_family_member_1
peptidyl_arginine_deiminase_type_II
ADAM_metallopeptidase_domain_8
taste_receptor_type_1_member_3

ITGB4
C17orf107

integrin_beta_4
chromosome_17_open_reading_frame_107

NT5M
SPANXC

5'3'-nucleotidase_mitochondrial
SPANX_family_member_C

SHANK3
VWA2

SH3_and_multiple_ankyrin_repeat_domains_3
von_Willebrand_factor_A_domain_containing_2

SH2B2
PDCD4-AS1
C22orf23
SSTR5
C11orf35
PLXND1
TMPRSS4
ANGPTL4

SH2B_adaptor_protein_2
PDCD4_antisense_RNA_1
chromosome_22_open_reading_frame_23
somatostatin_receptor_5
chromosome_11_open_reading_frame_35
plexin_D1
transmembrane_protease_serine_4
angiopoietin-like_4

RPSAP52
PPP1R32

ribosomal_protein_SA_pseudogene_52
protein_phosphatase_1_regulatory_subunit_32

ENTPD2
CCNA1

ectonucleoside_triphosphate_diphosphohydrolase_2
cyclin_A1
potassium_inwardlyrectifying_channel_subfamily_J_member_12
stathmin-like_3
CDC42_effector_protein_(Rho_GTPase_binding)_5

KCNJ12
STMN3
CDC42EP5
RUNX2
TMC8

runt-related_transcription_factor_2
transmembrane_channel-like_8

HELZ2
PPM1J

helicase_with_zinc_finger_2_transcriptional_coactivator
protein_phosphatase_Mg2+/Mn2+_dependent_1J

JAK3
AOC2

Janus_kinase_3
amine_oxidase_copper_containing_2_(retina-specific)

CADM4
LOXL2
PRTN3
ZNF862
KCNG1

cell_adhesion_molecule_4
lysyl_oxidase-like_2
proteinase_3
zinc_finger_protein_862
potassium_voltage-gated_channel_subfamily_G_member_1
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SPDEF

SAM_pointed_domain_containing_ets_transcription_factor

C15orf48
NOXA1

chromosome_15_open_reading_frame_48
NADPH_oxidase_activator_1

PHLPP1

PH_domain_and_leucine_rich_repeat_protein_phosphatase_1
extracellular_leucinerich_repeat_and_fibronectin_type_III_domain_containing_2
interleukin_32

ELFN2
IL32
ZNF837
B3GNT7
PDE9A
RP1L1
CRYL1
GPR156
RHBDL1
EXOC3L1
CYP24A1
LTBP2
HES4
ITGB2
DDO
ABO
TMC6

zinc_finger_protein_837
UDP-GlcNAc:betaGal_beta-13-Nacetylglucosaminyltransferase_7
phosphodiesterase_9A
retinitis_pigmentosa_1-like_1
crystallin_lambda_1
G_protein-coupled_receptor_156
rhomboid_veinlet-like_1_(Drosophila)
exocyst_complex_component_3-like_1
cytochrome_P450_family_24_subfamily_A_polypeptide_1
latent_transforming_growth_factor_beta_binding_protein_2
hairy_and_enhancer_of_split_4_(Drosophila)
integrin_beta_2_(complement_component_3_receptor_3_and_4
_subunit)
D-aspartate_oxidase
ABO_blood_group_(transferase_A_alpha_1-3-Nacetylgalactosaminyltransferase;_transferase_B_alpha_1-3galactosyltransferase)
transmembrane_channel-like_6

PTP4A3
DLC1

protein_tyrosine_phosphatase_type_IVA_member_3
deleted_in_liver_cancer_1

NIPAL4

ASPDH

NIPA-like_domain_containing_4
UDP-Gal:betaGlcNAc_beta_14_galactosyltransferase_polypeptide_2
aspartate_dehydrogenase_domain_containing

LTBP4
PLCH2

latent_transforming_growth_factor_beta_binding_protein_4
phospholipase_C_eta_2

CPM
TNFRSF18

carboxypeptidase_M
tumor_necrosis_factor_receptor_superfamily_member_18

B4GALT2

RIN1
STAT5A

Ras_and_Rab_interactor_1
signal_transducer_and_activator_of_transcription_5A

FLNC
MMP28
NCOR2

filamin_C_gamma
matrix_metallopeptidase_28
nuclear_receptor_corepressor_2
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RGL3
TRAPPC12
ARHGAP23
CLIC3
HES2
SULT2B1
CDC42EP1

ral_guanine_nucleotide_dissociation_stimulator-like_3
trafficking_protein_particle_complex_12
Rho_GTPase_activating_protein_23
chloride_intracellular_channel_3
hairy_and_enhancer_of_split_2_(Drosophila)
sulfotransferase_family_cytosolic_2B_member_1
CDC42_effector_protein_(Rho_GTPase_binding)_1

DOCK6
LIF

dedicator_of_cytokinesis_6
leukemia_inhibitory_factor

MYL2
CCBL1

myosin_light_chain_2_regulatory_cardiac_slow
cysteine_conjugate-beta_lyase_cytoplasmic

TLCD2
RNF112
TERT
IL3RA
RNPEPL1
MYO1G
MMRN2
LINC00313
PKN1
FAM83A
MICAL2
C2orf82
TRAPPC6A

TLC_domain_containing_2
ring_finger_protein_112
telomerase_reverse_transcriptase
interleukin_3_receptor_alpha_(low_affinity)
arginyl_aminopeptidase_(aminopeptidase_B)-like_1
myosin_IG
multimerin_2
long_intergenic_non-protein_coding_RNA_313
protein_kinase_N1
family_with_sequence_similarity_83_member_A
microtubule_associated_monooxygenase_calponin_and_LIM_d
omain_containing_2
chromosome_2_open_reading_frame_82
trafficking_protein_particle_complex_6A

RPS6KA2
CPLX1

ribosomal_protein_S6_kinase_90kDa_polypeptide_2
complexin_1

MAP1S
FAM132A
ABLIM2

microtubule-associated_protein_1S
family_with_sequence_similarity_132_member_A
actin_binding_LIM_protein_family_member_2
leucine_rich_repeat_and_fibronectin_type_III_domain_containin
g_4
p21_protein_(Cdc42/Rac)-activated_kinase_4
src-related_kinase_lacking_Cterminal_regulatory_tyrosine_and_Nterminal_myristylation_sites
acetylserotonin_O-methyltransferase-like
absent_in_melanoma_1-like
hexose-6-phosphate_dehydrogenase_(glucose_1dehydrogenase)
chondroitin_polymerizing_factor

LRFN4
PAK4
SRMS
ASMTL
AIM1L
H6PD
CHPF
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SERPINB9

LTB4R
FLNB

serpin_peptidase_inhibitor_clade_B_(ovalbumin)_member_9
potassium_voltage-gated_channel_Shawrelated_subfamily_member_4
leukotriene_B4_receptor
filamin_B_beta

SOX18
SERPINB1

SRY_(sex_determining_region_Y)-box_18
serpin_peptidase_inhibitor_clade_B_(ovalbumin)_member_1

KCNC4

Table 4.1b List of downregulated genes (p<0.05 and at least 3-fold reduction) under
low extracellular pH.
Gene Name
PEG10
HPGD
HIST1H4H
AGR2
MMP10
MMP1
SGCE
S100A4
MMP13
NBPF1

Description
paternally_expressed_10
hydroxyprostaglandin_dehydrogenase_15-(NAD)
histone_cluster_1_H4h
anterior_gradient_2_homolog_(Xenopus_laevis)
matrix_metallopeptidase_10_(stromelysin_2)
matrix_metallopeptidase_1_(interstitial_collagenase)
sarcoglycan_epsilon
S100_calcium_binding_protein_A4

ZNF326
ABHD12B
KIAA0101
HIST1H2BH
PFN2
C9orf3

matrix_metallopeptidase_13_(collagenase_3)
neuroblastoma_breakpoint_family_member_1
solute_carrier_family_7_(amino_acid_transporter_light_chain_L_syst
em)_member_8
zinc_finger_protein_326
abhydrolase_domain_containing_12B
KIAA0101
histone_cluster_1_H2bh
profilin_2
chromosome_9_open_reading_frame_3

ATP1B3
ARHGAP18
PIK3R3
ADRA1B
NOV
SLITRK6

ATPase_Na+/K+_transporting_beta_3_polypeptide
Rho_GTPase_activating_protein_18
phosphoinositide-3-kinase_regulatory_subunit_3_(gamma)
adrenoceptor_alpha_1B
nephroblastoma_overexpressed
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